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A B S T R A C T
Background
Nausea and vomiting remain a problem for childrenundergoing treatment formalignancies despite newantiemetic therapies.Optimising
antiemetic regimens could improve quality of life by reducing nausea, vomiting, and associated clinical problems. This is an update of
the original systematic review.
Objectives
To assess the effectiveness and adverse events of pharmacological interventions in controlling anticipatory, acute, and delayed nausea
and vomiting in children and young people (aged less than 18 years) about to receive or receiving chemotherapy.
Search methods
Searches included the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, LILACS, PsycINFO,
conference proceedings of the American Society of Clinical Oncology, International Society of Paediatric Oncology, Multinational
Association of Supportive Care in Cancer, and ISI Science and Technology Proceedings Index from incept to December 16, 2014, and
trial registries from their earliest records to December 2014. We examined references of systematic reviews and contacted trialists for
information on further studies. We also screened the reference lists of included studies.
Selection criteria
Two review authors independently screened abstracts in order to identify randomised controlled trials (RCTs) that compared a pharma-
cological antiemetic, cannabinoid, or benzodiazepine with placebo or any alternative active intervention in children and young people
(less than 18 years) with a diagnosis of cancer who were to receive chemotherapy.
Data collection and analysis
Two review authors independently extracted outcome and quality data from each RCT.When appropriate, we undertook meta-analysis.
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Main results
We included 34 studies that examined a range of different antiemetics, used different doses and comparators, and reported a variety of
outcomes. The quality and quantity of included studies limited the exploration of heterogeneity to narrative approaches only.
The majority of quantitative data related to the complete control of acute vomiting (27 studies). Adverse events were reported in 29
studies and nausea outcomes in 16 studies.
Two studies assessed the addition of dexamethasone to 5-HT3 antagonists for complete control of vomiting (pooled risk ratio (RR)
2.03; 95% confidence interval (CI) 1.35 to 3.04). Three studies compared granisetron 20 mcg/kg with 40 mcg/kg for complete control
of vomiting (pooled RR 0.93; 95% CI 0.80 to 1.07). Three studies compared granisetron with ondansetron for complete control of
acute nausea (pooled RR 1.05; 95% CI 0.94 to 1.17; 2 studies), acute vomiting (pooled RR 2.26; 95% CI 2.04 to 2.51; 3 studies),
delayed nausea (pooled RR 1.13; 95% CI 0.93 to 1.38; 2 studies), and delayed vomiting (pooled RR 1.13; 95% CI 0.98 to 1.29; 2
studies). No other pooled analyses were possible.
Narrative synthesis suggests that 5-HT3 antagonists aremore effective than older antiemetic agents, evenwhen these agents are combined
with a steroid. Cannabinoids are probably effective but produce frequent side effects.
Authors’ conclusions
Our overall knowledge of the most effective antiemetics to prevent chemotherapy-induced nausea and vomiting in childhood is
incomplete. Future research should be undertaken in consultation with children, young people, and families that have experienced
chemotherapy and should make use of validated, age-appropriate measures. This review suggests that 5-HT3 antagonists are effective
in patients who are to receive emetogenic chemotherapy, with granisetron or palonosetron possibly better than ondansetron. Adding
dexamethasone improves control of vomiting, although the risk-benefit profile of adjunctive steroid remains uncertain.
P L A I N L A N G U A G E S U M M A R Y
Drugs to prevent nausea and vomiting in children and young people undergoing chemotherapy
Background
The use of chemotherapy to treat cancer in children and young people can produce nausea (a sensation that one might vomit) and
vomiting. These extremely unpleasant sensations continue to be a problem despite better antiemetic (antisickness) drugs.
Review question
How effective are medications to prevent nausea and vomiting in children and young people undergoing chemotherapy?
Key results
We found only 34 properly randomised trials that had been undertaken in children, which examined 26 drug combinations. Trials
tended to report vomiting rather than nausea, even though nausea is generally a more distressing experience. We could make no firm
conclusions about which drugs are best, what dose of drug is most effective, or whether it is better to receive treatments orally (bymouth)
or intravenously (injected). It seems that the 5-HT3 antagonists (the ’trons’, for example ondansetron, granisetron, or tropisetron)
are better than older agents, and that adding dexamethasone to these drugs makes them even more effective. Further research should
consider what patients and families deem to be important, use established measures of nausea and vomiting, and attempt to use even
newer techniques in the undertaking of reviews in order to maximise the information available.
B A C K G R O U N D
Despite advances in antiemetic therapies, nausea and vomiting
continue to be a problem for children undergoing treatment
for malignancies (Holdsworth 2006), and are highly unpleas-
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ant (Dolgin 1989). The selection of an appropriate and effec-
tive antiemetic regimen has the potential to impact on quality
of life by eradicating or reducing the symptom and its associ-
ated clinical problems. Due to limited studies in children, optimal
paediatric dosing and scheduling of antiemetics remains uncer-
tain (Antonarakis 2004a; Roila 2005). This results in inconsisten-
cies and variation in prescribing, which is often underpinned by
personal preference and experience, as opposed to research-based
evidence (Foot 1994). In contrast, international evidence-based
guidelines have been produced for adults (Kris 2005).
The development of 5-HT3 antagonists, such as ondansetron, and
the wider use of corticosteroids have greatly improved the control
and reduction of chemotherapy-associated nausea and vomiting
(Culy 2001). However, the use of more intensive and emetogenic
chemotherapeutic agents means that nausea and vomiting are still
a major problem, and a significant number of children and young
people continue to experience emesis (Holdsworth 2006). Efforts
to reduce this side effect of treatment therefore must continue. In
addition, these symptoms are frequently a feature of the palliative
care phase and may have a detrimental effect on quality of life
(Wolfe 2000).
Nausea and vomiting can have profound physical and psycholog-
ical consequences. The physical consequences may include dehy-
dration, electrolyte imbalance, anorexia, weight loss, weakness, in-
creased susceptibility to infections, anddisruptionof normal child-
hood activities (Cotanch 1985). Chemotherapy-induced nausea
and vomiting are considered to be among the most aversive of
side effects, causing much distress to the child and family (Zeltzer
1991). When asked to identify what factors were distressing when
receiving chemotherapy, parents of children and young people
themselves reported physical concerns such as nausea and vomit-
ing as being particularly problematic (Hedstrom 2003). Interven-
tions that affect the physiological and psychological dimensions
of nausea and vomiting, as well as those that reduce the number
of episodes of emesis, are required to provide effective and holistic
management for these distressing and debilitating symptoms.
There appear to be distinct clinical phases of nausea and vomit-
ing related to chemotherapy. These commence with anticipatory
nausea and vomiting, symptoms that precede the administration
of chemotherapy, often following a previous aversive chemother-
apy experience. Estimates of the prevalence of anticipatory nau-
sea and vomiting have ranged from 20% to 30% (Dolgin 1985).
This experience responds poorly to pharmacological approaches
to antiemesis (Richardson 2007). Symptoms following adminis-
tration of chemotherapy, and within 24 hours, are defined as acute
nausea and vomiting. The incidence of this varies according to the
emetogenicity of the chemotherapy received, but without prophy-
laxis it can be upwards of 90% for some commonly used agents
(for example cisplatin) (Holdsworth 2006). Symptoms beyond 24
hours are described as delayed nausea and vomiting, and may oc-
cur in up to half of patients, usually after receiving platinum com-
pounds or alkylating agents (Holdsworth 2006).
Different antiemetic agents have different modes of action,
Antonarakis 2004b, and differing effectiveness (Antonarakis
2004a; Holdsworth 2006). Within a class of agents, varying side
effects may alter the overall utility of a drug (Sandoval 1999). Dif-
ferent dose schedules and routes of administration have been used
with the same agent with uncertain results (Sandoval 1999;White
2000).
In order to clearly define the limits of our knowledge of antiemetic
medications, we undertook a systematic review of pharmacological
approaches to prevent or reduce anticipatory, acute, and delayed
symptoms of nausea and vomiting in children and young people
who have cancer. This is an update of the original review published
in 2010 (Phillips 2010).
O B J E C T I V E S
Aim
To assess the effectiveness and adverse events of pharmacological
interventions in preventing nausea and vomiting in children and
young people (aged less than 18 years) about to receive or receiving
chemotherapy.
Objectives
• To assess the effectiveness of pharmacological interventions
in controlling anticipatory nausea and vomiting in children and
young people (aged less than 18 years) about to receive
chemotherapy.
• To assess the effectiveness of pharmacological interventions
in controlling acute and delayed nausea and vomiting in children
and young people (aged less than 18 years) receiving
chemotherapy.
• To determine the associated adverse events in participants
receiving pharmacological antiemetics.
• To assess the effect that pharmacological antiemetics have
on the quality of life of treated participants.
M E T H O D S
Criteria for considering studies for this review
Types of studies
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Randomised controlled trials (RCTs), where a pharmacological
antiemetic, cannabinoid, or benzodiazepine has been compared
with either placebo or an alternative active intervention.
Types of participants
Children and young people (less than 18 years) with a diagnosis
of cancer who have received chemotherapy and pharmacological
antiemetics.
Types of interventions
Standard pharmacological antiemetics used in the treatment of
chemotherapy-induced nausea and vomiting. These include (but






• dopamine blockers; and
• levomepromazine.
We excluded NK1 antagonists, which are the subject of another
Cochrane review (Tremont-Lukats 2007). We also excluded non-
pharmacological approaches from this review.
This review addressed the effectiveness of each agent in the pre-
vention and control of acute and delayed chemotherapy-induced
nausea and vomiting compared to placebo or active comparators.
This review also sought to address the effectiveness of the following
agents in the control of anticipatory nausea and vomiting com-
pared to placebo or any active comparator:
• cannabinoids;
• benzodiazepines.
Types of outcome measures
1. Complete control of nausea (no nausea and no use of rescue
medications) prior to chemotherapy delivery (anticipatory
phase), in the acute phase (first 24 hours of treatment with
chemotherapy), and in the delayed phase (after 24 hours of
treatment with chemotherapy) of nausea and vomiting.
2. Complete control of vomiting (no vomiting and no use of
rescue medications) prior to chemotherapy delivery (anticipatory
phase), and in the acute and delayed phases of nausea and
vomiting.
3. Adverse effects as defined by each trial found to be eligible
for this review.
4. Quality-of-life measures.
Where data on the complete control of nausea and vomiting were
absent, we estimated the effectiveness by analysis of the average
difference using a continuous measure of vomiting (for example
’number of vomits per day’) where available.
Search methods for identification of studies
Electronic searches
Weundertook searches in the following databases in order to iden-
tify relevant studies. We have reported full details of the search
strategies in Appendix 1.
• The Cochrane Central Register of Controlled Trials
(CENTRAL) (Cochrane Library - http://
www.thecochranelibrary.com/) from inception to 16 December
2014 (Issue 11, 2014).
• Ovid MEDLINE and Ovid MEDLINE In Process and
Other Non-Indexed Citations (Ovid Online - www.ovid.com)
from 1966 to 16 December 2014.
• EMBASE (Ovid Online - www.ovid.com) from 1980 to 16
December 2014.
• LILACS (Literatura Latino-Americana e do Caribe em
Ciências da Saúde) (http://bases.bireme.br/cgi-bin/wxislind.exe/
iah/online/) from inception to 17 December 2014.
• PsycINFO (Ovid Online - www.ovid.com) from 1806 to
16 December 2014.
We searched the followingproceedings abstracts.Wehave reported
full details of the search strategies in Appendix 2.
• American Society of Clinical Oncology (http://
www.asco.org) from 2008 to 2014.
• International Society of Paediatric Oncology (SIOP) (http:/
/www.siop.nl/) from 2008 to 2014.
• Multinational Association of Supportive Care in Cancer
(MASCC) (http://www.mascc.org/) from 2008 to 2014.
• ISI Science and Technology Proceedings (http://
wos.mimas.ac.uk/) from 2008 to 2014.
We also undertook searches for ongoing clinical trials using sev-
eral Internet resources. We have reported full details of the search
strategies in Appendix 3.
• International Cancer Research Portfolio (ICRP) (http://
www.cancerportfolio.org/) from inception to 16 December
2014.
• National Cancer Institute Clinical Trials PDQ (http://
www.cancer.gov/Search/SearchClinicalTrialsAdvanced.aspx)
from inception to 16 December 2014.
• National Cancer Research Institute (NCRI) (http://
www.ncri.org.uk/) from inception to 16 December 2014.
• Current Controlled Trials (mRCT Register) (http://
www.isrctn.com/) from inception to 16 December 2014.
• CinicalTrials.gov (http://clinicaltrials.gov/) from inception
to 16 December 2014.
• CenterWatch (http://www.centerwatch.com/) from
inception to 16 December 2014.
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Terminology
We identified the terms for the search strategies through discussion
between an Information Specialist and the rest of the research
team, by scanning the background literature, and by browsing the
MEDLINE thesaurus (MeSH). The Cochrane Childhood Cancer
Group also provided assistance. We searched all databases from
their inception to the date of the search. Searches covered the
inception of the database to 16 or 17 December 2014. We applied
no language or other restrictions.
Cochrane filters
The Cochrane Childhood Cancer Group suggested several search
filters for this review (Kremer 2014).
Study type: We used the sensitive trials filter developed by the
Centre for Reviews and Dissemination in MEDLINE. A trials
filter was developed for EMBASE based on the suggestions in the
Cochrane Handbook for Systematic Reviews of Interventions. This
was then adapted to run on PsycINFO. We did not use study type
filters in the other databases.
Childhood: The Cochrane Childhood Cancer Group has a filter
for children (age 0 to 18 years), which we used where appropriate
(Kremer 2014).
Childhood cancer: Since we were using a filter for children, we
adapted some aspects of the Cochrane Childhood Cancer Group
filter to prevent duplication. For instance, ’childhood cancer’ was
replaced by ’cancer’, since the concept of childhood was already
expressed in the age facet.
Searching other resources
We screened the references of any identified systematic reviews
and initiated personal communication with the authors of relevant
trials to request further information on published, unpublished,
or ongoing studies. We also screened the reference lists of included
studies. We employed no language restrictions.
Data collection and analysis
Selection of studies
After employing the search strategy, two review authors indepen-
dently screened each abstract to identify studies meeting the in-
clusion criteria. Discrepancies were resolved by consensus without
the need for final resolution using a third-party arbitrator. We ob-
tained in full any study that seemed to meet the inclusion criteria
on the grounds of the title, abstract, or both, for closer inspection
and inclusion or exclusion.
Data extraction and management
Two review authors independently extracted outcome data from
each includedRCT in the following categories: participants,meth-
ods, interventions, and outcome measurements of interest. We
recorded the outcome measurements as binary data (number of
participants with total control of nausea and vomiting during the
study period relative to the total number of participants evalu-
able for treatment) where possible. Discrepancies between review
authors were resolved by consensus. We sought clarification from
trial authors in cases of unclear or missing data.
Assessment of risk of bias in included studies
Two review authors independently extracted quality data from
each included RCT according to the following criteria: conceal-
ment of treatment allocation, blinding of the care provider, blind-
ing of the participants, blinding of the outcome assessor, ran-
dom sequence generation, and incomplete outcome data. We par-
tially assessed the potential for selective reporting of outcomes: we
checked the reported outcomes against where the study methods
stated which outcomes were collected. (In no cases did we check
the trial reported against the previously or separately published
trial protocol.)We also noted other potentials for bias. These were:
publication bias; the funder of the study, and any explanation as
to their role; and for cross-over studies the drop-out rates in each
phase of the trial. For all quality items, we used the definitions
as described in the module of the Cochrane Childhood Cancer
Group (Kremer 2014).Discrepancies between review authors were
resolved by consensus.
Data synthesis
When statistically appropriate, we combined the aggregate data to
obtain a pooled effect size. We planned to assess for effects related
to potential sources of bias, agent, dose, schedule, and route of
administration.
We entered data into RevMan 5.3, RevMan 2014, and planned
to undertake analyses according to the guidelines of the Cochrane
Handbook for Systematic Reviews of Interventions for eight separate
primary outcomes (Higgins 2011):
• complete control of nausea before chemotherapy treatment
(anticipatory nausea);
• complete control of vomiting before chemotherapy
treatment (anticipatory vomiting);
• complete control of nausea up to 24 hours of chemotherapy
treatment (acute nausea);
• complete control of nausea after 24 hours of chemotherapy
treatment (delayed nausea);
• complete control of vomiting up to 24 hours of
chemotherapy treatment (acute vomiting);
• complete control of vomiting after 24 hours of
chemotherapy treatment (delayed vomiting);
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• adverse event rate;
• quality-of-life measures.
Where appropriate, we examined outcomes when studies were
grouped by class of agent, dose, schedule, and route of adminis-
tration. Where data on the complete control of nausea and vom-
iting were absent, we estimated the effectiveness by analysis of the
average difference using a continuous measure of vomiting (for
example ’number of vomits per day’). Where possible, we used
an intention-to-treat analysis. Where data were missing, we un-
dertook an available case analysis (using all cases with available
data as the denominator). As this did not affect any pooled anal-
ysis, we did not undertake a sensitivity analysis. To maximise the
data from cross-over studies, we used paired data where available.
Where these were not available, we analysed studies as if they had a
traditional parallel design without accounting for paired data. We
calculated risk ratios and combined data using methods described
by Zou 2007.
We explored heterogeneity narratively, looking at alternative pop-
ulations, doses, and comparators. We compared random-effects
and fixed-effect models for pooled estimates when the calculated
I² value was greater than 50%.
R E S U L T S
Description of studies
Results of the search
The original search identified a total of 844 potentially useful in-
dividual articles (see Figure 1 for details). We identified 67 ar-
ticles for detailed screening. We identified one ongoing study
(NCT00429702 2007), and could not retrieve three studies (
Gómez 1995; Xu 1997; Zeng 1995). We attempted to contact
authors to clarify aspects of study design, data analysis, and to
retrieve specific data on those participants under 18 years of age.
We identified 27 articles reporting on 28 trials for inclusion in the
review. These included 1719 participants (median 30, range 12 to
428) and 2226 episodes (median 50.5, range 20 to 428).
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Figure 1. Flow diagram of study selection process original review (Phillips 2010).
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The updated search inDecember 2014 found a further 344 poten-
tially useful individual articles (see Figure 2 for details). We iden-
tified 12 articles for detailed screening. The previously identified
ongoing study had been terminated without publication of results
and was thus added to the Characteristics of excluded studies ta-
ble. We identified six new articles for inclusion in the review, and
identified that the ongoing study (NCT00429702 2007) had been
closed through poor accrual. The new studies included a further
304 participants and 869 episodes.
Figure 2. Flow diagram of study selection process for additional studies identified in 2014 update.
Included studies
The 34 included trials (28 from the original review and 6 from
the update) examined a wide range of different pharmacological
antiemetics, used different doses and comparators, and reported
a variety of outcomes. With the exception of Parker 2001, who
examined the use of ondansetron for intrathecal chemotherapy
only, and Nagel 2008, who examined the use of ondansetron and
fentanyl for intrathecal chemotherapy only, all trials looked at
the effectiveness of treatments on systemic chemotherapy-induced
nausea and vomiting.
Of the eight outcome measures specified in this review, no data
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were available from any study on anticipatory nausea or vomiting,
or for any validated quality-of-life measures. No trials compared
different durations of antiemetic medication.
Data on any outcomes beyond the first 24 hours of chemotherapy
were infrequently reported (Berrak 2007; Brock 1996; Emir 2013;
Noguera 2001; Sepulveda-Vildosola 2008; Siddique 2011).
Data on nausea were inconsistently reported using unvalidated
measurement scales (see Characteristics of included studies for
details). Theywere presented in thirteen trials (Brock1996;Dalzell
1986; Ekert 1979; Ekert 1979a; Emir 2013; Mehta 1986; Nagel
2008; Noguera 2001; Orchard 1999; Sandoval 1999; Sepulveda-
Vildosola 2008; Siddique 2011; Suarez 1994), with a further four
studies detailing a compound outcome of nausea, vomiting, or
both (Dick 1995; Mabro 2000; Sandoval 1999; Tejedor 1999).
The majority of quantitative data related to the complete control
of acute vomiting (27 trials) (Alvarez 1995; Basade 1996; Berrak
2007; Brock 1996; Chan 1987; Dick 1995; Ekert 1979; Ekert
1979a; Emir 2013; Graham-Pole 1986; Hirota 1993; Jaing 2004;
Komada 1999; Kurucu 2012;Mabro 2000;Marshall 1989;Mehta
1986; Nagel 2008; Noguera 2001; Orchard 1999; Parker 2001;
Safonova 1999; Sandoval 1999; Sepulveda-Vildosola 2008; Shi
2012; Siddique 2011; Suarez 1994). Adverse events were reported
in all except five studies (Kurucu 2012;Mehta 1986; Parker 2001;
Shi 2012; Tsuchida 1999), and not separately reported for children
in one study (Orchard 1999).
For three groups of studies, we undertook a pooled analysis. These
were for the addition of dexamethasone to 5-HT3 antagonists
(Analysis 1.1), for different doses of granisetron (Analysis 2.1),
and for ondansetron versus granisetron (Analysis 3.1 to Analysis
3.4). No other pooled analyses were possible (data for individual
studies are presented in Analysis 4.1 to Analysis 4.5). The quality
and quantity of included studies limited the exploration of het-
erogeneity.
Excluded studies
We have included information on the 43 studies excluded at the
detailed screening stage in the Characteristics of excluded studies
table. The most common reason for exclusion was that informa-
tion on participants less than 18 years old was unavailable. This
was almost always a very small proportion of the study population.
Risk of bias in included studies
See the ’Risk of bias’ section of the Characteristics of included
studies table and Figure 3 for the exact scores and the support for
the judgements made.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Random sequence generation was adequate, using computer-gen-
erated number or random number tables, in 12 studies (Alvarez
1995; Basade 1996; Berrak 2007; Graham-Pole 1986; Hahlen
1995; Orchard 1999; Safonova 1999; Sandoval 1999; Shi 2012;
Siddique 2011; Suarez 1994; White 2000), inadequate in one
(Jaing 2004), and not clearly reported in the remaining 21.
Allocation concealmentwas adequate in four studies (Berrak 2007;
Dick 1995; Graham-Pole 1986; Sandoval 1999), inadequate in
one (Jaing 2004), and not clearly reported in the other 29.
Blinding
Blinding was reported to have been undertaken in 14 studies
(Alvarez 1995; Berrak 2007; Brock 1996; Graham-Pole 1986;
Mabro 2000; Mehta 1986; Noguera 2001; Orchard 1999; Parker
2001; Safonova 1999; Sandoval 1999; Suarez 1994; Tejedor 1999;
White 2000). It was unclear in 15 studies (Basade 1996; Chan
1987; Dalzell 1986; Ekert 1979; Ekert 1979a; Emir 2013; Hahlen
1995; Hirota 1993; Marshall 1989; Nagel 2008; Sepulveda-
Vildosola 2008; Shi 2012; Siddique 2011; Swann 1979; Tsuchida
1999), with four of these uncertain because of the obvious and
frequent side effects of cannabinoids (Chan 1987; Dalzell 1986;
Ekert 1979; Ekert 1979a). Five studies were reported as not
blinded (Dick 1995; Jaing 2004; Komada 1999; Kurucu 2012;
Mehta 1997). No study reported any assessment of the quality of
blinding.We have provided details of the study rolesmasked to the
intervention in each outcome of each study in the Characteristics
of included studies table.
It was possible to attempt to assess the effect of blinding inAnalysis
1.1, where studies with unclear blinding, as compared to studies
where there was convincing blinding, were associated with a re-
duced estimate of the benefit of additional steroid to 5-HT3 an-
tagonists, in contrast to Analysis 2.1, where increasing certainty
in blinding was associated with a smaller benefit of higher-dose
granisetron. These assessments were based on very small num-
bers of studies (Hirota 1993 and Alvarez 1995 in Analysis 1.1
and Komada 1999, Tsuchida 1999, and Mabro 2000 for Analysis
2.1) and alternative explanatory covariates, such as type of added
steroid (in Analysis 1.1), the presence of paired data, and com-
pleteness of follow-up should also be assessed. In Analysis 3.1 to
Analysis 3.4, the only adequately blinded study, Noguera 2001,
favoured granisetron for some outcomes and ondansetron for oth-
ers.
Incomplete outcome data
In 16 studies (Berrak 2007; Chan 1987; Dick 1995; Ekert 1979;
Ekert 1979a; Emir 2013; Jaing 2004; Komada 1999; Kurucu
2012; Mabro 2000; Orchard 1999; Safonova 1999; Sandoval
1999; Sepulveda-Vildosola 2008; Shi 2012; Siddique 2011), there
were no dropouts or failures to complete cross-over. In three stud-
ies, uncertainty remained about the proportion of incomplete data
(Hahlen 1995; Marshall 1989; Swann 1979). In the remaining
15 studies, the proportion of missing data ranged from 2.9%, in
Basade 1996, to 50%, in Tejedor 1999.
No study obviously analysed participants according to the treat-
ment they had received rather than that to which they had been
randomised.
Selective reporting
We did not note selective reporting of particular outcomes within
trials in this review, although in three studies there was inadequate
detail to fully assess this (Noguera 2001; Suarez 1994; Swann
1979). It should be noted that this assessment was limited to the
reporting of methods and results within the published paper, and
in no cases referenced to a previously published protocol.
Other potential sources of bias
Two cross-over studies provided paired data (Hirota 1993; Jaing
2004). The remaining cross-over studies did not (Alvarez 1995;
Basade 1996; Berrak 2007; Chan 1987; Dalzell 1986; Ekert 1979;
Emir 2013; Mabro 2000; Marshall 1989; Nagel 2008; Parker
2001; Swann 1979; Tsuchida 1999), and were often unclear about
when dropouts occurred, with the potential for unequal drop-out
influencing the results of these studies.
The approach of using cross-over data in this review is supported
by empirical evidence of a lack of ’cross-over’ effects fromTsuchida
1999 (treatment effect P = 0.18, period effect P = 0.76, carry-over
P = 0.38).
Given so few comparable studies (Peters 2008), we could not rea-
sonably assess publication bias in this review. A relatively small
number of as-yet-unidentified studies could alter the results of this
review significantly. The lack of comparable studies also hampered
any assessment of the effect of study funding source.
Effects of interventions
The detailed results of this review can be seen in the control of
acute and delayed nausea (Analysis 4.1 and Analysis 4.2), acute
and delayed emesis (Analysis 4.2 and Analysis 4.3), and combined
outcomes (Analysis 4.4 and Analysis 4.5). As discussed previously,
the majority of results in this review related to the control of acute
emesis. Description of the effects of interventions separated by age
group, tumour type, or chemotherapy received was not possible.
11Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Benzodiazepines
One study used a combination ’cocktail’ of antiemetics that
included benzodiazepines: lorazepam, dexamethasone, metoclo-
pramide, and benztropine (Marshall 1989). A further study looked
at another ’cocktail’ including benzodiazepines: granisetron, dex-
amethasone, midazolam, and diphenhydramine (Emir 2013).
These are reported in the ’Other agents’ section below.
Cannabinoids
Four studies compared cannabinoids with alternative antiemet-
ics (Chan 1987; Dalzell 1986; Ekert 1979; Ekert 1979a). They
demonstrate markedly different results: the Ekert studies show
benefit of tetrahydrocannabinol over prochlorperazine and meto-
clopramide in controlling nausea as well as vomiting. For example,
for tetrahydrocannabinol versus prochlorperazine, complete con-
trol of acute nausea: risk ratio (RR) 20.7; 95% confidence interval
(CI) 17.2 to 36.2, and for complete control of vomiting: RR 19.0;
95% CI 13.7 to 26.3. Dalzell 1986 showed an improvement with
nabilone over domperidone in the reduction of nausea (nausea
severity score 1.5 compared with 2.5, P = 0.01 (Wilcoxon signed-
rank) on scale of 0 (none) to 3 (worst)). Chan 1987, the largest and
most recent study, demonstrated no benefit of tetrahydrocannabi-
nol over prochlorperazine in the control of emesis (complete con-
trol of vomiting RR 1.0; 95% CI 0.85 to 1.17). The heterogeneity
of studies meant no outcomes could be pooled.
Corticosteroids
Two studies examined steroids as a sole antiemetic agent. Basade
1996 looked at the comparative effectiveness of 8 mg/m² dexam-
ethasone to 1.5 mg/kg metoclopramide, and found dexametha-
sone to be significantly better (complete control of vomiting: RR
2.10; 95% CI 1.77 to 2.50). Mehta 1986 compared 4 mg/kg of
methylprednisolone to 0.5 mg/kg of chlorpromazine and found
no evidence of a difference (complete control of vomiting: RR 1.0;
95% CI 0.54 to 1.86).
Two studies examined the use of additive steroids combined with
5-HT3 antagonists (Alvarez 1995;Hirota 1993), which are pooled
in Analysis 1.1 and demonstrate good benefit. There was moder-
ate heterogeneity between these two studies (I² = 56%), with the
methylprednisolone study, Hirota 1993, having a lower estimate
of additional benefit compared with the added dexamethasone
study, Alvarez 1995. The fixed-effect and random-effects models
gave qualitatively similar results, with the expected increase in un-
certainty with the random-effects model and a relatively greater
weighting given to the smaller study (fixed-effect complete con-
trol of vomiting: RR 2.10; 95% CI 1.62 to 2.72, random-effects
complete control of vomiting: RR 2.03; 95% CI 1.35 to 3.04).
The use of steroids with non-5-HT3 antagonists compared with
5-HT3 antagonists is reviewed below.
No trials directly compared different types of steroid, dosing,
schedules, or routes of administration. Dexamethasone is the
steroid most frequently studied.
5-HT3 antagonists
Class
We found no direct comparisons of a single 5-HT3 antagonists
against single non-5-HT3 antagonists. Three studies examined
the effectiveness of 5-HT3 antagonists compared to concurrent
dexamethasone and either metoclopramide, in Dick 1995, or
chlorpromazine, in Hahlen 1995 and Tejedor 1999. Dick 1995
found ondansetron to be more effective than traditional antiemet-
ics (complete control of nausea and vomiting: RR 3.67; 95% CI
2.25 to 5.98). Hahlen 1995 showed granisetron to be more effec-
tive (median number of vomiting episodes 1.5 on ondansetron,
7 on chlorpromazine/dexamethasone), but using a different out-
come measure. Tejedor 1999 showed the chlorpromazine/dexam-
ethasone combination to be equally effective (complete control of
vomiting: RR 1.03; 95% CI 0.79 to 1.35). Nagel 2008 examined
the use of ondansetron, fentanyl, or placebo (4-way randomisa-
tion) after general anaesthesia and intrathecal methotrexate, and
showed a reduction in the number of vomit/retch episodes with
ondansetron (from 2 to 0.5 mean vomits in the 24 hours after the
procedure, P < 0.001)
Drugs
Five studies undertook direct comparisons of different 5-HT3 an-
tagonists: Noguera 2001 examined ondansetron, granisetron, and
tropisetron;Orchard1999 compared granisetron andondansetron
(both with dexamethasone); Jaing 2004 compared different
doses of granisetron and ondansetron (without dexamethasone);
Siddique 2011 also compared ondansetron with granisetron;
and Sepulveda-Vildosola 2008 compared ondansetron with
palonosetron.
The results of the three studies comparing ondansetron with
granisetron are pooled in Analysis 3.1 to Analysis 3.4. We found
no difference between the agents at preventing acute or delayed
nausea or delayed vomiting, however granisetron was significantly
better than ondansetron at preventing acute vomiting (RR 2.26;
95%CI 2.04 to 2.51).We could not include the results ofOrchard
1999 due to marked differences in the way efficacy was reported.
Sepulveda-Vildosola 2008 found a significant reduction in vomit-
ing on days 1 to 3 (P = 0.010, 0.023, and 0.028, respectively) and
nausea in days 1 to 4 (P = 0.001, 0.000, 0.000, and 0.002, respec-
tively) in children given palonosetron rather than ondansetron.
For the effect of additive dexamethasone, see above.
12Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Dose and schedule
Seven studies undertook dose comparisons of 5-HT3 antagonists.
Four studies compared granisetron doses. Berrak 2007 compared
10 mcg/kg with 40 mcg/kg. Their published results demonstrated
no significant difference between the doses (complete control of
acute vomiting: RR 0.88; 95% CI 0.70 to 1.10). The other three
studies, Komada 1999, Mabro 2000, and Tsuchida 1999, com-
pared granisetron 20 mcg/kg with 40 mcg/kg and were pooled in
Analysis 2.1. This demonstrated no clear difference in the doses
(complete control of vomiting: RR 0.93; 95% CI 0.80 to 1.07),
with very little heterogeneity (I² = 0%).
Two studies compared ondansetron doses. Brock 1996 compared
loading with 5 mg/m² and 10 mg/m², finding no advantage to
the higher dose (complete control of vomiting: RR 0.89; 95% CI
0.72 to 1.10, complete control of nausea: RR 1.01; 95% CI 0.81
to 1.25). Sandoval 1999 examined the effect of giving a single high
dose of 0.6 mg/kg ondansetron compared with dividing the dose
into four 0.15 mg/kg aliquots over 16 hours and found no clear
difference (complete control of vomiting: RR 0.94; 95% CI 0.49
to 1.79, complete control of nausea: RR 1.25; 95% CI 0.70 to
2.23).
Tropisetron doses are compared in a single dose-finding study
(Suarez 1994), which showed that doses of 0.1 mg/kg or greater
were more effective than placebo in controlling acute nausea and
vomiting.
Route
Only one uncompromised randomised study compared different
routes of administration of 5-HT3 antagonists. Safonova 1999
demonstrated that 8 mg oral ondansetron was equivalent to 5 mg/
m² when combined with intravenous dexamethasone (complete
control of vomiting: RR 1.04; 95% CI 0.62 to 1.75).
Other agents
Seven further studies examined the role of chlorpromazine (
Graham-Pole 1986; Marshall 1989), metoclopramide (Graham-
Pole 1986; Swann 1979), the combination ’cocktail’ of lorazepam,
dexamethasone, metoclopramide, and benztropine (LDMB) (
Marshall 1989), the combination ’cocktail’ of granisetron, dex-
amethasone, midazolam, and diphenhydramine (GDMD) (Emir
2013), hewei zhiou recipe (traditional Chinese herbal medicine)
(Shi 2012), hydroxyzine (Kurucu 2012), and fentanyl (Nagel
2008).
Graham-Pole 1986 demonstrated that chlorpromazine 0.5 mg/
kg was more effective than a similar dose of metoclopramide (re-
ported as mean number of vomits 1.8 (standard deviation (SD)
2.3) compared with 3.5 (SD 4.1) in 24 hours; duration of nausea
reduced to 4.2 hours (SD 6.4 hours) compared with 9.0 hours (SD
9.7 hours). Swann 1979 showed domperidone (up to 1 mg/kg)
was also more effective than metoclopramide 0.5 mg/kg (median
number of vomits in 36 hours was 1, compared with 4; median
duration of 0.5 hours versus 4.5 hours). Marshall 1989 showed an
improvement for the LDMB cocktail over 0.325 mg/kg chlorpro-
mazine (complete control of vomiting: RR 2.40; 95% CI 1.76 to
3.27). Emir 2013 showed slight superiority of the GDMD cock-
tail comparedwith ondansetron anddexamethasone in controlling
acute vomiting, but this did not reach statistical significance. There
was no difference between the GDMD cocktail compared with
ondansetron and dexamethasone in controlling delayed vomiting.
Shi 2012 showed less severe vomiting in participants given hewei
zhiou recipe in addition to ondansetron compared to those given
ondansetron alone (vomiting Z scores: -2.966, -3.256, -3.453, -
4.870, -3.627 for treatment cycles 2 to 6, P < 0.01), although
this effect was not seen in the first treatment cycle (vomiting Z
score -0.470, P > 0.05). Kurucu 2012 found complete control of
vomiting in 56% of participants given hydroxyzine in addition to
ondansetron, compared to 22% of participants given ondansetron
alone (P = 0.006). Nagel 2008 found no effect of adding fentanyl
(0.1 mg/kg) to ondansetron (0.15 mg/kg) on nausea or vomiting
after general anaesthesia and intrathecal methotrexate.
Adverse events
The reporting of adverse events varied markedly across different
studies, making any pooling of the results inappropriate. The com-
parison of proportions across different studies and drugs as an in-
direct assessment of relative harms is unlikely to be valid, as dif-
ferent measures and methods of reporting were used. We have re-
ported the results narratively below.
5-HT3 antagonists
A wide range of adverse events were noted for 5-HT3 antagonists.
Those reported in more than one study included:
• headache (10 studies; range from 2% in White 2000 to
53% in Mehta 1997);
• sedation/somnolence (five studies; range from 2% in Mabro
2000 to 66% in Mehta 1997);
• abdominal pain (six studies; range from 8% in White 2000
to 20% in Siddique 2011);
• dizziness/vertigo (three studies; 1% in Brock 1996, 2% in
Tejedor 1999, and 4% in Suarez 1994);
• diarrhoea (four studies; 2% in White 2000, 4% in Suarez
1994, 17% in Alvarez 1995, and 20% in Siddique 2011);
• constipation (four studies; proportion not noted in Jaing
2004, 5% in Tejedor 1999, 6% in Mabro 2000, 16.7%
(ondansetron) and 13.3% (granisetron) in Siddique 2011);
• fever (three studies; 3% in White 2000, 4% in Suarez 1994,
and 17% in Hahlen 1995);
• leg or muscle pains (two studies; 4% in Suarez 1994 and
6% in Dick 1995); and
• hypertension (two studies; 2% in Tejedor 1999 and 4% in
Suarez 1994).
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Five studies reported that no adverse events occurred (Berrak 2007;
Hirota 1993; Komada 1999; Safonova 1999; Sepulveda-Vildosola
2008). No clear dose-related or specific drug-related effects were
noted. For details see Table 1.
Cannabinoids
Of the three studies that examined cannabinoids, the main side
effects noted were:
• drowsiness (three studies; 80% in Chan 1987, 67% in
Dalzell 1986, and 28% in Ekert 1979);
• dizziness (two studies; 60% in Chan 1987 and 44% in
Dalzell 1986);
• mood alteration (three studies; 17% in Chan 1987 and
Dalzell 1986 and 5% in Ekert 1979); and
• increased appetite (two studies; 3% in Chan 1987 and 5%
in Dalzell 1986).
Isolated reports included ocular problems, orthostatic hypoten-
sion, muscle twitching, pruritis, vagueness, hallucinations, light-
headedness, and dry mouth. For details see Table 2.
As no study compared different cannabinoids, any differences in
side effects noted may be due to the study design or rigour of data
collection rather than different drugs or dosing schedules used.
Steroids
The adverse effects of steroids as an antiemetic are difficult to
assess in the studies undertaken. Only Basade 1996 reported the
adverse effects of dexamethasone; any adverse effects additional to
those from ondansetron were not reported in the study by Alvarez
1995, and no adverse events at all were noted in the studies of
Hirota 1993 and Safonova 1999. Further studies using steroids
are contaminated by the co-administration of chlorpromazine (
Hahlen 1995; Tejedor 1999), metoclopramide (Dick 1995), or as
part of the LDMB cocktail (Marshall 1989). For details see Table
1 and Table 3.
Metoclopramide
Four studies that reported adverse events assessedmetoclopramide.
These included:
• dystonia/extrapyramidal effects (two studies; 20% in
Graham-Pole 1986 and 2% in Basade 1996);
• drowsiness (two studies; approximately 8% in Ekert 1979
and Graham-Pole 1986).
Other effects were only noted in one of the studies, and included
depression, anorexia, abdominal pain, and headache. One study
(Swann 1979) reported no adverse events at all. For details see
Table 2 and Table 3.
Chlorpromazine
Two studies assessed chlorpromazine and found diarrhoea (12%
in Marshall 1989), extrapyramidal effects (4%) and drowsiness
(52%) (in Graham-Pole 1986). For details see Table 3.
Other agents
One study assessed midazolam and diphenhydramine and found
constipation (6.5%), sedation (12.9%), and hypotension (6.5%)
(Emir 2013).
D I S C U S S I O N
This update of our systematic review of antiemetic medication
for prophylaxis and treatment of chemotherapy-induced nausea
and vomiting in children and young adults found only 34 ran-
domised controlled trials, examining 28 different pairs of combi-
nations of antiemetic medication approaches. This adds just three
studies to the original review of 2010. The quality of individual
studies remains moderate, with relatively small numbers and wide
confidence intervals limiting our ability to draw conclusions. The
lack of adequate numbers of studies undertaking similar com-
parisons limits any interpretation of the threats to randomisation
that were identified. The outcomes reported were largely related
to emesis, rather than the more patient-relevant and often more
distressing experience of nausea. Where nausea was reported, it
was done without the use of validated symptom scales. Nausea,
assessed through self report, is particularly difficult and complex
to assess. Children, certainly the very young, may not have the lan-
guage skills to describe their experience, or understand what they
are being asked to describe, and this may in part explain the focus
on vomiting. Direct comparisons of different agents and classes
of agents were generally lacking: granisetron may help with acute
vomiting (but not nausea, or delayed vomiting or nausea) more
than ondansetron. A single study suggests palonesotron may be
better than ondansetron. When we sought information to assess
the risk-benefit balance, by addressing reporting of adverse events,
this was still extremely variable. Our search strategy was extensive
and we attempted through contact with authors to extract any use-
ful data from studies with primarily adult participants. We sought,
found, and included trials published in the Japanese, Latin Amer-
ican, and non-English language European literature in order to
reduce the possibility of language-related publication bias (Egger
1997; Juni 2002; Moher 2003).
Four years on fromour original review, our overall picture of which
are the most effective antiemetics to prevent chemotherapy-in-
duced nausea and vomiting in childhood remains incomplete and
imprecise.
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What can we conclude from such sparse data? We continue to
propose tentative clinical implications and restate our firm research
questions.
The practical, clinical conclusions from these trials are that 5-HT3
antagonists seemmore effective than older antiemetic agents, even
when those agents are combined with a steroid. Of the 5-HT3
receptor antagonists, granisetron may be more effective at higher
doses, and granisetron and palonosetron may be more effective
than ondansetron, though the small quantity of evidence cautions
against firm conclusions. The addition of dexamethasone to the 5-
HT3 antagonist of choice doubles the chance of complete control
of acute vomiting. The use of steroids as an antiemetic, despite ev-
idence of efficacy, remains controversial. The lowest effective dose
is unclear. Pre-clinical studies suggest that glucocorticoids reduce
sensitivity of a wide range of cell lines to chemotherapy agents
(Meyer 2006; Zhang 2006). However, no clinical studies have
found an association between steroids as an antiemetic and wors-
ened outcomes. Cannabinoids are probably effective, but produce
high levels of side effects, which may be experienced as adverse
by some patients, but not by others. We cannot clearly define a
route, schedule, or dose of maximal efficiency of any antiemetic
medication from this review.
A further issue is the duration of the antiemesis, particularly with
respect to multi-day/multi-agent chemotherapy (Einhorn 2005;
Roila 2005). Although the available evidence deals with antiemetic
therapy given alongside chemotherapy, the optimal duration of
antiemesis following the last dose of chemotherapy is unclear. In
various studies, antiemesis is reported as being given during che-
motherapy (for example Alvarez 1995), or for up to two (for exam-
pleWhite 2000) to three (for example Brock 1996) days following
the last administration of emetogenic chemotherapy. There ap-
pear to be no randomised trials that address this issue, and in this
respect the duration of chemotherapy antiemesis is unclear and
should be a subject of further investigation, particularly by way of
randomised controlled trials.
The research questions that emerge concern the need for good
primary research: the conduct of new paediatric symptom control
studies and the use of basic pharmacological and pharmacogenetic
studies to support our understanding of the drugs’ use. They also
raise questions about the methods used in Cochrane systematic
reviews, namely the need to explore alternative approaches in order
to incorporate data from adult studies and also maximise the use
of data from existing studies.
It is acknowledged that studies in children for drugs that have
a feasible use in this age group are an ethical imperative, WHO
2007, and increasingly have a financial benefit, Sammons 2009.
Such studies should use appropriate doses as assisted by both adult
and pharmacokinetic studies, and patient-important valid out-
comes. In this setting, the complete control of nausea has been
shown to be most important, with young people distinguishing
between nausea and vomiting when selecting the five most impor-
tant symptoms to feature on an electronic questionnaire (Gibson
2007). Nausea is consistently mentioned as a frequent distressing
problemby children and young people, with vomiting described as
relatively less distressing (Hedstrom 2003;Williams 2006), and to
some vomitingmay be a relief fromnausea.Despite the availability
of validated instruments to measure nausea in children (Dupuis
2006; Linder 2005), these did not feature in the papers reviewed.
Where nausea was assessed, see for example Berrak 2007, no vali-
dated instrument was used. Rather, participants between one and
23 years old recorded a combined assessment of nausea, retching,
and vomiting in a diary, which failed to reveal the intensity of
nausea as distinct. Future research would benefit from the use of
validated instruments that capture both patient and caregiver per-
ceptions if we are really to understand the cancer care experience
(Dodd 2001; Hinds 2008).
This review has very few trials from which to assess the effects of
publication bias, or make firm conclusions. As such, it is relatively
’unstable’, as a few further trials addressing one specific issue may
tip the clinical conclusion in an alternative direction. The inter-
ventions for which meta-analysis was possible have weaknesses.
The meta-analysis assessing the effectiveness of additional steroid
has only two studies and moderate heterogeneity. The use of a
random-effects model assumes a difference (heterogeneity) in the
underlying populations or interventions, and undertaking such
an analysis with few (less than five) studies has been questioned
(Higgins 2009). The heterogeneity may come from the use of dif-
ferent steroids, and this would be supported by the findings of
Basade 1996 andMehta 1986, whose studies, if read simplistically,
show that dexamethasone is a better antiemetic than methylpred-
nisolone. However, their comparator agents (metoclopramide and
chlorpromazine, respectively) are not shown to be equal in the
study by Graham-Pole 1986. Analysis with simple binary meta-
analysis cannot hope to address these problems. The studies also
have a different reported quality of blinding. In the meta-analysis
of different doses of granisetron (Analysis 2.1), there are three dif-
ferent strengths of certainty about the blinding applied to outcome
measurement in the studies, and the results follow the expected
pattern of having greater observed benefit for the unblinded study.
This may mean that the estimate is an exaggeration. The meta-
analytic comparison of granisetron and ondansetron for control
of acute vomiting only included three studies, and was driven very
strongly by the smallest study, which showed different results than
the other two.
Alternative approaches to maximising data from existing studies
using network meta-analysis in order to develop robust indirect
comparisons remain a developing field of inquiry (Sutton 2008).
Such network meta-analyses have provided useful answers to un-
solved questions in adult cardiology (Caldwell 2005), neurology
(Wilby 2005), and mental health (Cipriani 2009). An extension
of this technique, using adult studies as an explicit starting point
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fromwhich to assess the studies in children, is worth examining to
answer this question and to provide a clear and potential method-
ological base fromwhich to examine other symptom control ques-
tions in paediatric oncology, but it has not yet been taken up and
developed.
Our conclusions remain fundamentally unchanged from 2010:
the key research questions that require new evidence should be
decided in consultation with children, young people, and families
that have undergone chemotherapy and been exposed to the med-
ications and their effects. It has been acknowledged there may be
a mismatch between available research evidence and the research
preferences of consumers (Glass 2002; Tallon 2000), and across
a range of services and clinical care, there is an expectation of
increased and more meaningful consumer participation and in-
volvement, including children (Coyne 2006; Darbyshire 2005).
As clinicians, we suggest that three key points may be: to clarify
further whether there are any patient-important differences in the
5-HT3 antagonists; to understand the most beneficial dose and
duration of dexamethasone; and to clarify the role of new agents
(for example substance P antagonists) in the prevention of che-
motherapy-induced nausea.
The prevention and treatment of nausea, and to a lesser extent
vomiting, caused by chemotherapy in children and young people
remains an important issue for their quality of life. Continued
research into improving our understanding of and refining our
therapies is required. Until then, the results of this review suggest
that 5-HT3 antagonists with dexamethasone added are effective
in patients who are to receive highly emetogenic chemotherapy,
although the exact risk-benefit profile of the addition of steroid
remains uncertain.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Our overall picture of which antiemetics are the most effective in
preventing chemotherapy-induced nausea and vomiting in child-
hood remains incomplete and imprecise. With this caveat, we sug-
gest that 5-HT3 antagonists with dexamethasone added are ef-
fective in patients who are to receive highly emetogenic chemo-
therapy, although it remains uncertain how the proven benefit of
steroid in reducing emesis balances with the in vitro reduction in
chemotherapy sensitivity.
Implications for research
Children and young people rate therapy-related symptoms as the
overall most difficult aspect of cancer treatment (Moody 2006;
Woodgate 2003; Woodgate 2005). Traditionally, symptom man-
agement has emphasised medical management with administra-
tion of pharmacologic agents. More recently, a holistic approach
to symptom management has been recommended, which in-
cludes both pharmacological and non-pharmacological interven-
tions (Rheingans 2008). We would recommend this approach to
care and hence advocate that the key questions that require new
evidence should be decided in consultation with children, young
people, and families that have undergone chemotherapy and been
exposed to themedications and their effects. Symptom experiences
are a family affair, as symptoms are multifaceted and reciprocal,
impacting thewhole family and its overall quality of life (Woodgate
2003). We would recommend that any new research questions
should take into consideration multidimensional approaches to
the symptom experience of children and young people.
As clinicians, we suggest that three key points are still likely to be
to:
1. clarify potential patient-important differences between the
5-HT3 antagonists;
2. understand the most beneficial dose and duration of
dexamethasone; and
3. clarify the role of new agents (e.g. substance P antagonists)
in the prevention of chemotherapy-induced nausea.
We would recommend that any future research make use of val-
idated, age-appropriate measures. Additionally, future research
would benefit from the use of validated instruments that capture
both patient and caregiver perceptions if we are really to under-
stand the cancer care experience (Hinds 2008).
The role of newer techniques ofmeta-analysis in paediatrics, which
incorporate Bayesian approaches, is as yet uncertain and is a press-
ing area for further methodological research that may produce sig-
nificant clinical benefits.
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C H A R A C T E R I S T I C S O F S T U D I E S




Participants Participants aged 9 years median (range 3 to 18 years) with solid tumours receiving
“emetogenic” chemotherapy. 19/33 participants were male. Cross-over on an identical
course. Chemotherapy consisted of 4- to 5-day ifosfamide 1.8 g/m² to 2.5 g/m² plus
doxorubicin 25 mg/m² or etoposide 100 mg/m²; 4- to 5-day cisplatin 20 to 120 mg/m²
plus etoposide, doxorubicin, cyclophosphamide, or ifosfamide; 1-day cyclophosphamide
1.2 g to 2.2 g plus doxorubicin and actinomycin; 1-day carboplatin 700 mg/m², or day
1 of ABVD
Interventions Ondansetron, IV, 0.15 mg/kg 30 minutes prior to chemo, then BD on chemotherapy
for 1 to 5 days
Ondansetron, IV, 0.15 mg/kg 30 minutes prior to chemo, then BD on chemotherapy
Dexamethasone either 4 mg/m² QDS or 8 mg/m² BD (depended on institution)
Outcomes Emetic episode defined as vomiting that produced liquid or any retches within a 5-
minute period. A complete response was achieved if no emetic episode occurred. 1 or
2 emetic episodes constituted a “major response”. 3 to 5 episodes constituted a “minor
response”. More than 5 episodes, the need for rescue medication, or participant with-
drawal constituted a “failure”
Unvalidated nausea assessment of “none, a little, some, a lot”
Notes Data reported by episode; no paired analysis possible. 2 institutions and dexamethasone
dose varied (see above)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stated randomised
Allocation concealment (selection bias) Unclear risk Randomisation list given to institutional pharmacy
Blinding (performance bias and detection
bias)
Acute nausea
Low risk Blinding of care provider: yes
Blinding of participant: yes
Blinding of outcome assessors: yes (as above, and nursing staff )
Blinding (performance bias and detection
bias)
Acute vomiting
Low risk Blinding of care provider: yes
Blinding of participant: yes
Blinding of outcome assessors: yes (as above, and nursing staff )
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Alvarez 1995 (Continued)
Blinding (performance bias and detection
bias)
Other outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk 33 had 1 course, 25 had 2 courses (= 58 episodes). Loss after
course 1 = 1 death, 3 PD, and 4 “failures”
Selective reporting (reporting bias) Low risk All outcomes reported





Participants 27 children with any paediatric malignancy, receiving chemotherapy that included cy-
clophosphamide > 600 mg/m². Median 7 years (range 3 to 14 years)
Interventions Dexamethasone 8 mg/m² IV 15 minutes prior to chemotherapy
Metoclopramide 1.5 mg/kg IV 15 minutes prior to chemotherapy
Outcomes Emetic episodes recorded by doctor, participant, or nurse. Unvalidated vomiting as-
sessment, where participant report or clinicians opinion of the participant’s nausea was
recorded as “None, moderate, severe”
Notes Paired data not presented
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stated randomised
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
Acute nausea
Unclear risk Blinding of care provider: unclear
Blinding of participant: unclear
Blinding of outcome assessors: unclear
Stated “single blind” but no further information
Blinding (performance bias and detection
bias)
Acute vomiting
Unclear risk Blinding of care provider: unclear
Blinding of participant: unclear
Blinding of outcome assessors: unclear
Stated “single blind” but no further information
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Basade 1996 (Continued)
Blinding (performance bias and detection
bias)
Other outcomes
High risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk 1 participant (2.9%) failed to complete cross-over; no reason
given
Selective reporting (reporting bias) Low risk All outcomes reported




Participants 18 participants with optic pathway glioma receiving carboplatin. 7.7 years median age
(1 to 23 years)
Interventions Granisetron, OD, IV, 10 mcg/kg
Granisetron, OD, IV, 40 mcg/kg
Outcomes Diary collected vomiting assessment
Notes Investigator helpfully supplied data to extract paired, first cross-over analysis for imme-
diate and delayed vomiting
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The dose of granisetron was randomly ordered by two physi-
cians (ET and BB).”
Allocation concealment (selection bias) Low risk “The study blind was maintained using a double dummy tech-
nique ... two physicians (ET and BB) who were not involved in
either the collection or evaluation of self-report diary cards or
safety assessments.”
Blinding (performance bias and detection
bias)
Acute nausea
High risk Not reported
Blinding (performance bias and detection
bias)
Acute vomiting
Low risk “granisetron was prepared accordingly by the pharmacy in sim-
ilar syringes labelled simply ’granisetron”’
Blinding of care provider: yes
Blinding of participant: yes
Blinding of outcome assessors: yes (as above, and nursing staff )
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Berrak 2007 (Continued)
Blinding (performance bias and detection
bias)
Other outcomes
Low risk Combined nausea and vomiting
“granisetron was prepared accordingly by the pharmacy in sim-
ilar syringes labelled simply ’granisetron”’
Blinding of care provider: yes
Blinding of participant: yes
Blinding of outcome assessors: yes (as above, and nursing staff )
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete data available
Selective reporting (reporting bias) Low risk All outcome data available
Other bias Low risk No other risk of bias noted
Brock 1996
Methods RCT
Participants All participants scheduled to receive highly emetogenic chemotherapy except brain tu-
mours, cerebral metastases, or meningeal leukaemia, where highly emetogenic chemo-
therapy was defined as:
Actinomycin > 15 mcg/kg or > 0.45 mg/m²
Carboplatin > 400 mg/m²
Cisplatin > 20 mg/m²
Cyclophosphamide > 500 mg/m²
Cytosine > 500 mg/m²
Dacarbazine > 250 mg/m²
Daunorubicin > 40 mg/m²
Doxorubicin > 40 mg/m²
Ifosfamide > 1 g/m²
Methotrexate > 5 g/m²
Mitoxantrone > 8 mg/m²
Nitrogen mustard > 6 mg/m²
Epirubicin > 45 mg/m²
Mean age 8.5 years (range 1.9 to 16.7 years), 102/160 participants were male
Interventions Ondansetron 5 mg/m² IV over 15 minutes immediately prior to chemotherapy, then 8
hours and 16 hours after initial dose. From day 2 ondansetron given orally < 1 m² 4 mg
TDS, > 1 m² 8 mg TDS, continued for 3 days after last day of chemotherapy or 5 days
if nausea and vomiting persisted
Ondansetron 10 mg/m² IV over 15 minutes immediately prior to chemotherapy, then 5
mg/m² IV 8 hours and 16 hours after initial dose. From day 2 ondansetron given orally <
1 m² 4 mg TDS, > 1 m² 8 mg TDS, continued for 3 days after last day of chemotherapy
or 5 days if nausea and vomiting persisted
Outcomes Emesis recorded as timing and number of episodes of vomiting or retching. Unvalidated
nausea assessment of “none, mild or severe” on diary cards
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
Acute nausea
Low risk “The anti-emetic loading dose of ondansetron was blinded to
the clinicians, the patients, the parents and the nurses.”
Blinding of care provider: yes
Blinding of participant: yes
Blinding of outcome assessors: yes
Blinding (performance bias and detection
bias)
Acute vomiting
Low risk “The anti-emetic loading dose of ondansetron was blinded to
the clinicians, the patients, the parents and the nurses.”
Blinding of care provider: yes
Blinding of participant: yes
Blinding of outcome assessors: yes
Blinding (performance bias and detection
bias)
Other outcomes
High risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk 14 participants (15%) of 5 mg/m² lost to follow-up, and 13
participants (14%) of 10mg/m² lost to follow-up. Data for these
participants not included
Selective reporting (reporting bias) Low risk All outcomes reported




Participants Any paediatric malignancy, but patients in whom a chemotherapy cycle was previously
shown to cause moderate to severe drug-induced nausea and vomiting
No participants received cisplatin. Participants had not previously been treated with
either nabilone or prochlorperazine. 30 participants, median age 11.8 years (3.5 to 17.
8 years), gender not specified
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Chan 1987 (Continued)
Interventions Nabilone orally (1mg capsules) starting 8 to 12hours prior to chemotherapy and repeated
2 or 3 times a day according to dosage schedule
Original schedule:
18 to 27 kg 1 mg BD
27.1 to 36 kg 1 mg TDS
> 36 kg 2 mg BD
Modified schedule:
< 18 kg 0.5 mg BD
18 to 30 kg 1 mg BD
> 30 kg 1 mg TDS
Prochlorperazine orally (capsules) starting 8 to 12 hours prior to chemotherapy and
repeated 2 or 3 times a day according to dosage schedule
Original schedule:
18 to 27 kg 5 mg BD
27.1 to 36 kg 5 mg TDS
> 36 kg 10 mg BD
Modified schedule:
< 18 kg 2.5 mg BD
18 to 30 kg 5 mg BD
> 30 kg 5 mg TDS
Outcomes Vomiting was recorded as the total number of episodes of vomiting or retching
Notes Study supported by a grant from Eli Lilly (company supplying nabilone)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
Acute nausea
High risk Not reported
Blinding (performance bias and detection
bias)
Acute vomiting
Unclear risk Medical staff and participants/parents not aware of drug allo-
cation, but nabilone has frequent, significant, and immediately
identifiable side effects
Blinding of care provider: unclear
Blinding of participant: unclear
Blinding of outcome assessors: unclear
Blinding (performance bias and detection
bias)
Other outcomes
High risk Not reported
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Chan 1987 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 10 withdrawals, all included in toxicity assessments. 4 change of
chemotherapy after cycle 1; 2 unable to cope with diagnosis and
treatment; 2 received other antiemetics during study period; 2
cycle 2 of chemotherapy deferred because of severe dizziness/
drowsiness after a single 2mgdose of nabilone prior to treatment
Selective reporting (reporting bias) Low risk All outcomes reported




Participants Any paediatric malignancy, as long as 2+ identical courses of chemotherapy scheduled.
Only 1 with cisplatin, mainly had high-dose cyclophosphamide. Mean age 8.6 years
(range 0.8 to 17 years), 18/23 participants were male
Interventions Nabilone 0.5 mg BD if < 18 kg, 1 mg BD if 18 to 36 kg, 1 mg TDS if > 36 kg
Domperidone 5 mg TDS if < 18 kg, 10 mg TDS if 18 to 36 kg, 15 mg TDS if > 36 kg
Outcomes Vomiting episodes recorded. Nausea assessed as “0, 1, 2, 3”, but unclear if as a visual
analogue scale or integers to circle/tick. No indication of the performance of the tool (e.
g. is “3” three times as bad as “1”?)
Notes Only data on completers were used
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
Acute nausea
High risk Not reported
Blinding (performance bias and detection
bias)
Acute vomiting
High risk Not reported
Blinding (performance bias and detection
bias)
Other outcomes
Unclear risk Medical staff and participants/parents not aware of drug allo-
cation, but nabilone has frequent, significant, and immediately
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Dalzell 1986 (Continued)
identifiable side effects
Blinding of care provider: unclear
Blinding of participant: unclear
Blinding of outcome assessors: unclear
Incomplete outcome data (attrition bias)
All outcomes
High risk Only 18/23 participants (78%) completed cross-over; 2 lost
from nabilone arm, 3 from metoclopramide arm
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk No other risk of bias noted
Dick 1995
Methods RCT
Participants 30 participants with ALL undergoing MRC Intensification (daunorubicin, etoposide,
and high-dose cytarabine). Age and gender of participants not recorded
Interventions 15 participants received ondansetron 3 to 8 mg/m² given pre-chemotherapy, then BD
initially IV then orally for 3 days (dose < 0.6 m² - load 3 mg/m², maint 3 mg/m² or 2
mg; 0.6 to 1.2 m² - load 3 mg/m², maint 3 mg/m² or 4 mg; > 1.2 m² - load 8 mg, maint
8 mg)
15 participants received metoclopramide 10 mg/m² IV QDS for 3 days, with 2.5 mg
procyclidine. Dexamethasone 4 mg/m² IV then 2 mg/m² TDS IV or PO
Outcomes Vomiting numbers recorded on diary cards. Unvalidated nausea assessment of “not
feeling very sick at all, feeling sick, feeling very sick”
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated “block balanced” but no further detail given
Allocation concealment (selection bias) Low risk “coding held in the pharmacy.”
Blinding (performance bias and detection
bias)
Acute nausea
High risk Not reported
Blinding (performance bias and detection
bias)
Acute vomiting
High risk Not reported
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Dick 1995 (Continued)
Blinding (performance bias and detection
bias)
Other outcomes
High risk Combined nausea and vomiting
Blinding of care provider: no
Blinding of participant: no
Blinding of outcome assessors: no
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts or withdrawals
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias High risk 10 of 15metoclopramide patients were switched to ondansetron
during D1, so ’contaminated’ any ostensibly randomised com-
parisons of later efficacy
Ekert 1979
Methods RCT
Multiple randomisations per participant, each independent
Participants Any paediatric malignancy. Age and gender not recorded.
Any regimen of chemotherapy, with mixed emetogenicity. No platinums. Courses in-
cluded: high-dose methotrexate (7.5 g/m²) = 6, lower-dose vincristine (.625 g/m²) = 5,
doxorubicin (60) = 2, vincristine-doxorubicin-dacarbazine = 7, vincristine-prednisolone-
cyclophosphamide-doxorubicin = 4, cytosine-cyclophosphamide-asparaginase = 6, cy-
tarabine/6Thioguanine = 3, 5FU-doxorubicin-actinomycinD = 2, lomustine-vincristine
= 7
Interventions Tetrahydrocannabinol 10 mg/m², given at -2, 4, 8, 16, and 24 hours around chemo-
therapy administration
Metoclopramide 5 mg (for < 0.7 m² participants) or 10 mg (for > 0.7 m² participants)
at -2, 8, 16, and 24 hours. Placebo given at +4 hours
Outcomes Nurse recorded outcomes (as inpatient) or parent/child recordeddiary.Vomiting episodes
and nausea (present/absent) reported
Notes First of 2 randomisations, second reported as Ekert 1979a
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
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Ekert 1979 (Continued)
Blinding (performance bias and detection
bias)
Acute nausea
Unclear risk Stated “double blinded”, but cannabinoids
have frequent, significant, and immediately
identifiable side effects
Blinding of care provider: unclear
Blinding of participant: unclear
Blinding of outcome assessors: unclear
Blinding (performance bias and detection
bias)
Acute vomiting
Unclear risk Stated “double blinded”, but cannabinoids
have frequent, significant, and immediately
identifiable side effects
Blinding of care provider: unclear
Blinding of participant: unclear
Blinding of outcome assessors: unclear
Blinding (performance bias and detection
bias)
Other outcomes
High risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Full report of data
Selective reporting (reporting bias) Low risk -
Other bias Unclear risk Stopped early because of failure of efficacy




Multiple randomisation per participant, each independent
Participants Any paediatric malignancy. Age and gender not recorded.
Any regimen of chemotherapy, with mixed emetogenicity. No platinums. Courses in-
cluded: high-dose methotrexate (7.5 g/m²) = 4, doxorubicin (60) = 3, vinc-procarbazine-
pred-lomustine = 12, vinc-pred-cyclo-doxorubicin = 2, cytosine-cyclo-asparaginase = 2,
5FU-dox-actinoD = 2, lomustine-vinc = 2, vinc-actinomycinD = 4, vinc-6MP-dox-pred
= 3, cytosines-daunorubicin/doxorubicin = 2
Age and sex not reported
Interventions Tetrahydrocannabinol 10 mg/m², given at -2, 4, 8, 16, and 24 hours around chemo-
therapy administration
Prochlorperazine - tablets. Complex schedule
SA 0.7 to 1.1 m² = 5 mg at -2, 8, 16, 24 hours
SA 1.1 to 1.4 m² = 10 mg at -2, 8 hours and 5 mg at 16, 24 hours
SA > 1.1 m² = 10 mg at -2, 8, 16, 24 hours
Placebo given at +4 hours
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Ekert 1979a (Continued)
Outcomes Nurse recorded outcomes (as inpatient) or parent/child recordeddiary.Vomiting episodes
and nausea (present/absent) reported
Notes Second randomisation in paper (see Ekert 1979)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
Acute nausea
Unclear risk Stated “double blinded”, but cannabinoids
have frequent, significant, and immediately
identifiable side effects
Blinding of care provider: unclear
Blinding of participant: unclear
Blinding of outcome assessors: unclear
Blinding (performance bias and detection
bias)
Acute vomiting
Unclear risk Stated “double blinded”, but cannabinoids
have frequent, significant, and immediately
identifiable side effects
Blinding of care provider: unclear
Blinding of participant: unclear
Blinding of outcome assessors: unclear
Blinding (performance bias and detection
bias)
Other outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Full report of data
Selective reporting (reporting bias) Low risk -




Participants Paediatric patients (age 1 to 16 years, median 7 years; 13/23 male) receiving cisplatin-
containing chemotherapy regimens
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Emir 2013 (Continued)
Interventions Granisetron 0.04 mg/kg plus dexamethasone 0.2 mg/kg
Granisetron 0.04 mg/kg, dexamethasone 0.2 mg/kg, midazolam 0.04 mg/kg, and
diphenhydramine 2.5 mg/kg
Outcomes Number of vomits
Severity of nausea (no definition of how this was defined given in paper)
Use of rescue therapy
Adverse events
Complete response was defined as no nausea or vomiting, partial response as 1 or 2
vomits but no need for rescue therapy, no response as more than 3 emetic episodes or
need for rescue therapy
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
Acute nausea
Unclear risk Not stated
Blinding (performance bias and detection
bias)
Acute vomiting
Unclear risk Not stated
Blinding (performance bias and detection
bias)
Other outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants accounted for in results
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Unclear risk Paired data not provided
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Graham-Pole 1986
Methods RCT
Participants 50 participants with any paediatric malignancy (included osteogenic sarcoma, AML,
Ewing’s sarcoma, and lymphoma). Chemotherapy included aggressive regimens, e.g.
cisplatin 100 to 120 mg/m², methotrexate > 7.5 g/m², cyclophosphamide > 900 mg/m²,
and anthracyclines > 60 mg/m². 12 participants were receiving conditioning for BMT
with cytosine 3 g/m²/dose or melphalan 60 mg/m²/dose
40/50 participants were younger than 10 years, and 34/50 male
Interventions 24 participants received metoclopramide 0.5 mg/kg/dose IV infusion over 15 minutes
beginning 30 minutes before chemotherapy and repeated every 3 hours for 5 doses
26 participants received chlorpromazine 0.5 mg/kg/dose IV infusion over 15 minutes
starting 30 minutes before chemotherapy and repeated every 3 hours for 5 doses
Outcomes Unvalidated nausea assessment with duration in hours recorded. Number and volume
of vomits recorded. Unclear who recorded the information
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants assigned with a random numbers table
Allocation concealment (selection bias) Low risk Drugs prepared in inpatient pharmacy. Both supplied to ward in
50 ml normal saline and labelled with “Reglan Study” and par-
ticipant’s name. Participants and clinicians did not know which
antiemetic was being used
Blinding (performance bias and detection
bias)
Acute nausea
High risk Not reported
Blinding (performance bias and detection
bias)
Acute vomiting
High risk Not reported
Blinding (performance bias and detection
bias)
Other outcomes
Low risk Not clear who collected data, but “only pharmacy were aware of
drug allocation”
Blinding of care provider: yes
Blinding of participant: yes
Blinding of outcome assessors: yes
Incomplete outcome data (attrition bias)
All outcomes
High risk Participants who experienced an extrapyramidal reaction had no
further data recorded
Selective reporting (reporting bias) Low risk -
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Graham-Pole 1986 (Continued)
Other bias High risk Discrepancy on numbers of participants who had received prior
chemotherapy
19/24 participants in metoclopramide group had prior chemo-
therapy




Participants 88 children with any paediatric malignancy, excluding primary or secondary brain tu-
mour. Majority of children had soft tissue sarcomas
Chemotherapy consisted of high-dose ifosfamide treatment (> = 3 g/m²) for 2 or 3 con-
secutive days. Other cytostatic agents, e.g. dactinomycin, doxorubicin, and vincristine,
were permitted to be given concurrently (as in most cases) or after completion of ifos-
famide administration
Mean age was 9.5 years, and around half the children were boys
Interventions 46 children received granisetron 20 mcg/kg in 20 ml saline by IVI over 5 minutes, then
ifosfamide infusion started
Up to 2 further doses granisetron 20 mcg/kg per dose within each 24-hour period if
moderate or severe nausea or any vomiting (to a maximum of 60 mcg/kg in 24 hours)
42 children received dexamethasone 2 mg/m² by IVI 30 minutes before ifosfamide
infusion started, then again at 8 and 16 hours, plus chlorpromazine 0.5 mg/kg by IVI
25 minutes before start of ifosfamide and at 4- to 6-hourly intervals (reduced to 0.3 mg/
kg loading dose and 0.3 to 0.5 mg/kg 4- to 6-hourly after reports of unacceptable levels
of sedation in some children)
Outcomes Assessment of severity of nausea and frequency of vomiting or retching episodes during
6 hourly periods by hospital staff
At end of treatment period, subjective assessment of overall response to antiemetic ther-
apy (very good, good, average, poor, very poor) made by clinician
Unvalidated nausea assessment of none, mild, moderate, severe. Vomiting episodes
recorded
Notes Stopped early due to emerging evidence of effectiveness and tolerability of granisetron
over control therapy (88 out of 100 planned participants)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation code. Randomisation strat-
ified to ensure that 2- and 3-day ifosfamide treatments were
evenly represented in both groups
Allocation concealment (selection bias) Unclear risk Not stated
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Hahlen 1995 (Continued)
Blinding (performance bias and detection
bias)
Acute nausea
Unclear risk “Children were assigned on a single blind basis”.
Blinding of care provider: unclear
Blinding of participant: yes
Blinding of outcome assessors: unclear
Blinding (performance bias and detection
bias)
Acute vomiting
Unclear risk “Children were assigned on a single blind basis”.
Blinding of care provider: unclear
Blinding of participant: yes
Blinding of outcome assessors: unclear
Blinding (performance bias and detection
bias)
Other outcomes
Unclear risk “Children were assigned on a single blind basis”.
Blinding of care provider: unclear
Blinding of participant: yes
Blinding of outcome assessors: unclear
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “... all children were included in efficacy and safety analysis”,
however unclear if any missing outcomes at each time point
Selective reporting (reporting bias) Low risk -
Other bias Unclear risk Stopped early due to emerging evidence of effectiveness and





Participants Any paediatric malignancy: osteosarcoma (2), NHL (3), “brain tumour” (2), ALL (2),
other sarcoma (3)
Any chemotherapy protocol that was moderate or highly emetogenic, with 2 courses
required (for cross-over)
Mean age 10.8 years (4 to 18 years), 8/12 were male
Interventions Granisetron 40 mcg/kg IV 30 minutes prior to Rx
Granisetron 40 mcg/kg IV 30 minutes prior to Rx plus methylprednisolone 10 mg/kg
(max 500 mg) IV
Outcomes Parents reported vomiting episodes
Notes Paired data
Risk of bias
Bias Authors’ judgement Support for judgement
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Hirota 1993 (Continued)
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
Acute nausea
Unclear risk Not stated
Blinding (performance bias and detection
bias)
Acute vomiting
Unclear risk Not reported
Blinding (performance bias and detection
bias)
Other outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk 2 participants did not complete cross-over. Data not given
Selective reporting (reporting bias) Low risk -
Other bias Low risk No other risk of bias noted
Jaing 2004
Methods RCT
Open-label, 2-period cross-over study
Participants ALL with no CNS involvement who were receiving cyclophosphamide 300 mg/m² plus
etoposide 300 mg/m² or cyclophosphamide 1000 mg/m² alone
Mean 88 months old with 21/33 males
Interventions Oral granisetron single dose 1 hour before administration of chemotherapy
25 to 50 kg 0.5 mg
> 50 kg 1 mg
Ondansetron 0.15 mg/kg IV 1 hour before chemotherapy and 4 hours after the first
dose. Oral dose given 8 hours after the first dose
Outcomes Parent reported number of vomiting episodes
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
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Jaing 2004 (Continued)
Random sequence generation (selection
bias)
High risk Allocated on the basis of hospital number
Allocation concealment (selection bias) High risk Sequence generated by hospital number
Blinding (performance bias and detection
bias)
Acute nausea
High risk Blinding of care provider: no
Blinding of participant: no
Blinding of outcome assessors: no
Blinding (performance bias and detection
bias)
Acute vomiting
High risk Blinding of care provider: no
Blinding of participant: no
Blinding of outcome assessors: no
Blinding (performance bias and detection
bias)
Other outcomes
High risk Blinding of care provider: no
Blinding of participant: no
Blinding of outcome assessors: no
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up
Selective reporting (reporting bias) Low risk -




Participants Participants with ALL receiving either high-dose methotrexate (3 g/m²) or high-dose
cytarabine plus dexamethasone (3 g/m²). Participants aged 6.3 years (range 1 year to 14
years), 21/49 male
Interventions Granisetron 20 mcg/kg given immediately prior to chemotherapy at 30 min IV infusion
Granisetron 40 mcg/kg given immediately prior to chemotherapy at 30 min IV infusion
Outcomes Episodes of vomiting recorded
Notes 13 participants receiving Ara-C had their treatment ’contaminated’ by the concurrent
use of dexamethasone as an antiemetic
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
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Komada 1999 (Continued)
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
Acute nausea
High risk Blinding of care provider: no
Blinding of participant: no
Blinding of outcome assessors: no
Blinding (performance bias and detection
bias)
Acute vomiting
High risk Not reported
Blinding (performance bias and detection
bias)
Other outcomes
High risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts in 24-hour data, all completed cross-over
Selective reporting (reporting bias) Low risk Unclear if the HD-MTX and high-dose Ara-C were identified
a priori
Other bias High risk Participants receiving Ara-C had their treatment ’contaminated’
by the concurrent use of dexamethasone
Kurucu 2012
Methods RCT
Participants 18 children (aged 35 to 207 months) receiving chemotherapy including at least 1 highly
emetogenic drug. A total of 70 courses were studied
Interventions 36 courses - participants received ondansetron 5 mg/m2
34 courses - participants received ondansetron 5 mg/m2 plus hydroxyzine 1 mg/kg
Outcomes Control of emesis using Skoup-Smith criteria (Skoup 1990; Smith 1990)
Patient performance using Lansky Play-Performance Scale (Lansky 1987)
Degree of symptoms using Symptom Distress Scale (McCorcle 1998)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details
Allocation concealment (selection bias) Unclear risk No details
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Kurucu 2012 (Continued)
Blinding (performance bias and detection
bias)
Acute nausea
High risk Placebo not used; hydroxyzine given regularly (orally) through-
out chemotherapy course; participants, caregivers, and observers
would be aware of additional drug being given
Blinding (performance bias and detection
bias)
Acute vomiting
High risk Placebo not used; hydroxyzine given regularly (orally) through-
out chemotherapy course; participants, caregivers, and observers
would be aware of additional drug being given
Blinding (performance bias and detection
bias)
Other outcomes
High risk Placebo not used; hydroxyzine given regularly (orally) through-
out chemotherapy course; participants, caregivers, and observers
would be aware of additional drug being given
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants accounted for
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk No other risk of bias noted
Mabro 2000
Methods RCT
Participants Any patients with paediatric malignancy excluding cerebral tumours associated with
vomiting
Receiving moderately emetogenic chemotherapy:
• carboplatin (>= 500 mg/m²)
• cyclophosphamide (>= 500 to 900 mg/m²) in combination with other agents
• ifosfamide (1 to 2.4 g/m²)
• actinomycin D (>= 1.5 mg/m²)
• cisplatin (20 to 49 mg/m²)
• methotrexate (> 8 g/m²)
• adriamycin (>= 60 mg/m²)
• cytarabine (1 to 2.9 g/m²)
OR highly emetogenic chemotherapy:
• cyclophosphamide (>= 1000 mg/m²)
• cisplatin (>= 50 mg/m²)
• ifosfamide (>= 2.5 g/m²)
• nitrogen mustard (> 6 mg/m²)
• dacarbazine (> 200 mg/m²)
• cytarabine (>= 3 g/m²)
Patients were excluded if: received more than 1 course of chemotherapy in preceding
year, radiation therapy in preceding 7 days or during course of study, emetogenic che-
motherapy in preceding 7 days, persistent nausea or vomiting in preceding 48 hours, a
food intolerance in preceding 4 days, intestinal obstruction, corticosteroids outside of
chemotherapy treatment, other antiemetic treatments, cerebral tumours associated with
vomiting, liver enzymes outside of specified range
Mean age 7.8 years (range 1 year to 16 years). 177/294 participants were male
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Mabro 2000 (Continued)
Interventions 143 participants received 20 µg/kg oral granisetron (orange flavoured) - diluted to 0.2
mg/ml and given 1 hour before and again 6 to 12 hours after the start of chemotherapy
on each day of chemotherapy for 1 to 5 days (depending on chemotherapy regimen)
151 participants received 40 µg/kg oral granisetron (orange flavoured) - diluted to 0.2
mg/ml and given 1 hour before and again 6 to 12 hours after the start of chemotherapy
on each day of chemotherapy for 1 to 5 days (depending on chemotherapy regimen)
Outcomes Number of vomits recorded every 6 hours for each 24-hour period. Nausea assessed by
unvalidated self/parent report using a scale of “none, mild, moderate, severe”
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States “randomised”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
Acute nausea
High risk Not reported
Blinding (performance bias and detection
bias)
Acute vomiting
Low risk States “double blind”
Blinding of care provider: yes
Blinding of participant: yes
Blinding of outcome assessors: yes
Blinding (performance bias and detection
bias)
Other outcomes
Low risk States “double blind”
Blinding of care provider: yes
Blinding of participant: yes
Blinding of outcome assessors: yes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis reported by day
Selective reporting (reporting bias) Low risk -
Other bias Low risk Randomisation stratified by emetogenic level of chemotherapy
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Participants Any child with a paediatric malignancy on any chemotherapy protocol including BMT
conditioning in 6 participants, who had a second course planned. Median age 7 years (4
to 15 years), with 17/26 male
Interventions Chlorpromazine 0.825 mg/kg QDS IV for 4 doses
Cocktail. Metoclopramide (IV) 2 mg/kg/dose 0, 2, 6, 12 hours. Dexamethasone (IV) 0.
7 mg/kg 0 hours. Benzatropine (IV) 0.02 mg/kg/dose 0, 6 hours. Lorazepam (PO) 0.05
mg/kg/dose, 1 hour and 12 hours
Outcomes Recorded number and duration of vomiting using ?structured interview - unclear
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
Acute nausea
Unclear risk Not reported
Blinding (performance bias and detection
bias)
Acute vomiting
Unclear risk “Double blinded” but unclear how effective the placebos would
be
Blinding of care provider: unclear
Blinding of participant: unclear
Blinding of outcome assessors: unclear
Blinding (performance bias and detection
bias)
Other outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 2/26 did not complete the cross-over
Selective reporting (reporting bias) Low risk -
Other bias Unclear risk 6/26 on conditioning regimens given after 24 hours - could there
be a carry-over effect?
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Mehta 1986
Methods RCT
Participants 20 children with paediatric malignancy who had any chemotherapy containing adri-
amycin > 30 mg/m², cisplat > 100 mg/m², MTX > 300 mg/m², actinoD > 0.5 mg/m²,
cyclo > 1 g/m² or lomustine > 6 mg/m², and had experienced significant toxicity on a
previous course. Gender not specified
Interventions 10 participants received chlorpromazine 0.5mg/kg IV 30minutes prior to chemotherapy
10 participants received methylprednisolone 4 mg/kg IV 30 minutes prior to chemo-
therapy
Outcomes Unvalidated assessment of nausea by clinicians for the first 2 to 8 hours, then parental/
participant report. Duration of nausea and number of vomiting episodes recorded
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
Acute nausea
Low risk “Double blinded”
Blinding of care provider: yes
Blinding of participant: yes
Blinding of outcome assessors: yes
Blinding (performance bias and detection
bias)
Acute vomiting
High risk “Double blinded”
Blinding of care provider: yes
Blinding of participant: yes
Blinding of outcome assessors: yes
Blinding (performance bias and detection
bias)
Other outcomes
High risk “Double blinded”
Blinding of care provider: yes
Blinding of participant: yes
Blinding of outcome assessors: yes
Incomplete outcome data (attrition bias)
All outcomes
High risk 3 not evaluated, unclear from which arm or even if excluded
prior to randomisation
Selective reporting (reporting bias) Low risk -
Other bias Low risk No other risk of bias noted
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Mehta 1997
Methods RCT
Participants 28 participants with need for stem cell (bone marrow) transplantation (allograft or
autologous), including those receiving TBI. Median age 8 years (range 4 to 12 years),
9/15 male in ondansetron group. Median age 9.5 years (range 4 to 17), 9/13 male in
perphenazine group
Interventions 15 participants received ondansetron loading 0.15mg/kg then 0.45mg/kg as continuous
infusion
13 participants received perphenazine 0.06 mg/kg loading and 0.4 mg/kg per 24 hours
continuous infusion), plus diphenhydramine 1 mg/kg QDS
Outcomes “Continuous” recording of vomiting and retching (events within 5 minutes considered
as a single episode). Probably nursing staff recording outcomes
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
Acute nausea
High risk Not reported
Blinding (performance bias and detection
bias)
Acute vomiting
High risk Not reported
Blinding (performance bias and detection
bias)
Other outcomes
High risk Blinding of care provider: no
Blinding of participant: no
Blinding of outcome assessors: no
Incomplete outcome data (attrition bias)
All outcomes
High risk 3 not evaluated, unclear from which arm or even if excluded
prior to randomisation
Selective reporting (reporting bias) Low risk -
Other bias Low risk No other risk of bias noted
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Nagel 2008
Methods RCT cross-over trial
Participants 25 participants aged 4 to 17 years with newly diagnosed ALL
Interventions Placebo + placebo
Fentanyl 1 mg/kg + placebo
Placebo + ondansetron 0.15 mg/kg
Fentanyl 1 mg/kg + ondansetron 0.15 mg/kg
Outcomes Number of vomits
Severity of nausea (reported by parents based on disruption of daily activity)





Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States randomised but details not provided
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
Acute nausea
Low risk Double-blind, placebo used
Blinding (performance bias and detection
bias)
Acute vomiting
Low risk Double-blind, placebo used
Blinding (performance bias and detection
bias)
Other outcomes
Low risk Double-blind, placebo used
Incomplete outcome data (attrition bias)
All outcomes
High risk 11 of 24 participants did not complete all 4 trial arms
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Unclear risk Paired data not provided
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Noguera 2001
Methods RCT
Randomised per course, but multiple episodes per participant
Participants Participants with 6 different neoplasms: ALL, Wilms, brain, rhabdomyosarcoma, ovar-
ian germ cell, and retinoblastoma, who received highly or very highly emetogenic che-
motherapy (cisplatin, high-dose carboplatin, high-dose cyclophosphamide, high-dose
methotrexate, or daunorubicin). Median age 6 years (3 months to 14 years), 6/12 par-
ticipants were male
Interventions Ondansetron 0.45 mg/kg IV 15 minutes after chemotherapy
Tropisetron 0.20 mg/kg IV 15 minutes after chemotherapy
Granisetron 20 µg/kg IV 15 minutes after chemotherapy
Outcomes Number of vomiting episodes recorded by nurses in charge of care
Notes Translation and extraction by Moacyr Nobre, InCor HCFMUSP, São Paulo, Brazil
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
Acute nausea
Low risk Stated “double blinded” but no further de-
tail
Blinding of care provider: yes
Blinding of participant: yes
Blinding of outcome assessors: yes
Blinding (performance bias and detection
bias)
Acute vomiting
Low risk Stated “double blinded” but no further de-
tail
Blinding of care provider: yes
Blinding of participant: yes
Blinding of outcome assessors: yes
Blinding (performance bias and detection
bias)
Other outcomes
High risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk 11 episodes in total (~15%) missing data -
not clear out of which groups
Selective reporting (reporting bias) Unclear risk Could not be determined
Other bias Low risk No other risk of bias noted
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Orchard 1999
Methods RCT
Participants 187 paediatric patients (not all had malignancy) receiving any of the standard condi-
tioning regimens (chemotherapy alone or with TBI) for autologous or allogeneic BMT.
Age ranged from 2 to 16 years. Gender split not given
Interventions 90 participants received granisetron: 10 mcg/kg/dose before start of chemo/TBI then
every 12 hours, and placebo: continuous infusion 5% dextrose (until day of transplant
- day 0)
97 participants received ondansetron: loading dose 0.15 mg/kg before start of chemo/
TBI then continuous infusion 0.03 mg/kg/hour rounded to nearest 0.1 mg (until day of
transplant - day 0), and placebo: intermittent 5% dextrose administered every 12 hours
All participants: dexamethasone 10 mg/m²/day (max 10 mg). For breakthrough nausea/
vomiting, lorazepam 0.05 mg/kg IV or promethazine 0.25 to 1.0 mg/kg IV every 4 to
6 hours. Other antiemetic support was considered as needed
Outcomes Child recorded nausea using an unvalidated ’faces’ approach (nausea VAS: smiling/
frowning faces)
Nurse recorded episodes of vomiting
Notes 73% of participants had TBI in addition to conditioning chemotherapy
Authors provided additional graphical data showing the changes in nausea scores and
episodes of vomiting in children over time
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk States randomised, but no further details given
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
Acute nausea
Low risk States double-blind. Placebo used.
Blinding of care provider: yes
Blinding of participant: yes
Blinding of outcome assessors: yes
Blinding (performance bias and detection
bias)
Acute vomiting
Low risk States double-blind. Placebo used.
Blinding of care provider: yes
Blinding of participant: yes
Blinding of outcome assessors: yes
Blinding (performance bias and detection
bias)
Other outcomes
High risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk No withdrawals/dropouts confirmed by author
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Orchard 1999 (Continued)
Selective reporting (reporting bias) Low risk -





Participants Participants with ALL receiving intrathecal chemotherapy +/- maintenance chemother-
apy. Median age 6 years (range 2 to 17 years). 12/26 were male
Interventions High-dose ondansetron 0.45 mg/kg IV 15-minute infusion 30 minutes prior to lumbar
puncture
Low-dose ondansetron 0.15 mg/kg IV 15-minute infusion 30 minutes prior to lumbar
puncture
Placebo (saline) IV 15-minute infusion 30 minutes prior to lumbar puncture
Outcomes Parental report of number of vomiting episodes recorded
Notes Given the low potential of chemotherapy itself, seemsmore like a trial of post-anaesthetic
antiemetics than of chemotherapy-induced emesis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
Acute nausea
High risk Not reported
Blinding (performance bias and detection
bias)
Acute vomiting
Low risk States double-blind. No further details.
Blinding of care provider: yes
Blinding of participant: yes
Blinding of outcome assessors: yes
Blinding (performance bias and detection
bias)
Other outcomes
High risk Not reported
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Parker 2001 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Dropouts between cross-overs (1 before placebo, 2 before on-
dansetron 0.45 mg/kg)
Selective reporting (reporting bias) Low risk -
Other bias Low risk No other risk of bias noted
Safonova 1999
Methods RCT
Participants Any child with a paediatric malignancy whose body surface area was < 1.6 m², who had
no pre-existing nausea and vomiting problems, and had no previous Rx with antiemetics
within 24 hours or systematic Rx with steroids or benzodiazepines
Chemotherapy was of moderate or high emetogenicity containing dactinomycin > 15
mg/kg, carboplatin > 300 mg/m², cisplatin > 20 mg/m², cyclophosphamide > 500 mg/
m², dacarbazine > 200 mg/m², etoposide > 200 mg/m², ifosfamide > 1000 mg/m²,
methotrexate > 3000 mg/m², cytarabine > 100 mg/m²
Age not given. 23/52 participants were male
Interventions Ondansetron 8 mg PO BD plus 4 to 8 mg dexamethasone IV
Ondansetron 5 mg/m² IV BD plus 4 to 8 mg dexamethasone IV
Outcomes Unvalidated parent/participant-reported nausea outcome, graded from 0, none to 3,
strong. Number of episodes of vomiting also recorded
Notes Translation by Prof David Reeves
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stated randomised
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
Acute nausea
High risk Not reported
Blinding (performance bias and detection
bias)
Acute vomiting
Low risk States double blind. No further details.
Blinding of care provider: yes
Blinding of participant: yes
Blinding of outcome assessors: yes
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Safonova 1999 (Continued)
Blinding (performance bias and detection
bias)
Other outcomes
High risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss of participants
Selective reporting (reporting bias) Low risk -
Other bias Low risk No other risk of bias noted
Sandoval 1999
Methods RCT
Participants Any newly diagnosed patient with malignancy undergoing moderately or highly emeto-
genic chemotherapy
Moderately: anthracyclines 25 to 60 mg/m², carboplatin 175 mg/m², cyclophosphamide
1200 to 1500 mg/m², and etoposide 100 mg/m²
Highly: cisplatin 100 mg/m², cyclophosphamide > 1500 mg/m², dacarbazine 375 mg/
m², and actinomycin 1.35 mg/m²
Median age 4 years (range 0.25 to 18 years) with 16/31 participants male
Interventions 16 participants received ondansetron 0.6 mg/kg (max 32 mg) IV over 30 minutes before
chemotherapy then 3 normal saline doses given every 4 hours starting 4 hours after
ondansetron
15 participants received ondansetron 0.15 mg/kg (max 8 mg) IV over 30 minutes before
chemotherapy then every 4 hours for a total of 4 doses
Outcomes Unvalidated nausea assessment tool, unclear who recorded nausea. Scaled:
1. No nausea or emesis
2. Nauseous but able to eat
3. Nauseous and unable to eat
4. Emesis
Number of vomiting episodes and time-to-first-vomit were recorded
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Pharmacist not involved in participant care using a random
number table
Allocation concealment (selection bias) Low risk Allocation by pharmacist not involved with participant care
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Sandoval 1999 (Continued)
Blinding (performance bias and detection
bias)
Acute nausea
Low risk States double-blind. No further details.
Blinding of care provider: yes
Blinding of participant: yes
Blinding of outcome assessors: yes
Blinding (performance bias and detection
bias)
Acute vomiting
Low risk States double-blind. No further details.
Blinding of care provider: yes
Blinding of participant: yes
Blinding of outcome assessors: yes
Blinding (performance bias and detection
bias)
Other outcomes
Low risk States double-blind. No further details.
Blinding of care provider: yes
Blinding of participant: yes
Blinding of outcome assessors: yes
Incomplete outcome data (attrition bias)
All outcomes
High risk No loss of participants
Selective reporting (reporting bias) Low risk -
Other bias Unclear risk Multi-dose group had 7/15 (47%) highly emetogenic chemo-




Participants Participants under 16 years old with solid tumours undergoing a total of 100 courses of
highly emetogenic chemotherapy (number of individual participants not stated, therefore
it is unclear whether some participants had more than 1 course included in the study)
Interventions In 50 courses, participants received ondansetron 8 mg/m2 IV every 8 hours
In 50 courses, participants received palonosetron 0.25 mg IV single dose
Outcomes Number of emetic events
Severity of nausea (reported by parents/guardians as impact on oral intake)
Side effects (though not reported which were assessed)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
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Sepulveda-Vildosola 2008 (Continued)
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
Acute nausea
Unclear risk Double blind. Difference in dose frequency may have meant
participants were not actually blinded
Blinding (performance bias and detection
bias)
Acute vomiting
Unclear risk Double blind. Difference in dose frequency may have meant
participants were not actually blinded
Blinding (performance bias and detection
bias)
Other outcomes
Unclear risk Double blind. Difference in dose frequency may have meant
participants were not actually blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants accounted for
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk No other risk of bias noted
Shi 2012
Methods RCT
Participants 80 children with solid tumours
Interventions 40 children received ondansetron 4 mg IV
40 children received ondansetron 4 mg IV plus hewei zhiou recipe (traditional Chinese
medicine) oral
Outcomes Self reported vomiting scores (number of vomits and intensity of vomiting)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random digit table
Allocation concealment (selection bias) Unclear risk No details
Blinding (performance bias and detection
bias)
Acute nausea
Unclear risk No details
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Shi 2012 (Continued)
Blinding (performance bias and detection
bias)
Acute vomiting
Unclear risk No details
Blinding (performance bias and detection
bias)
Other outcomes
Unclear risk No details
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants accounted for in results
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk No other risk of bias noted
Siddique 2011
Methods RCT
Participants 60 children aged 4 to 11 scheduled to receive high-dose methotrexate
Interventions 30 received ondansetron 4 mg
30 received granisetron 1 mg
Outcomes Modified MANE scale (self reported occurrence of nausea, retching, or vomiting)




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stratified using random sampling
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
Acute nausea
Low risk Double blind
Blinding (performance bias and detection
bias)
Acute vomiting
Low risk Double blind
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Siddique 2011 (Continued)
Blinding (performance bias and detection
bias)
Other outcomes
Low risk Double blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants accounted for
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk No other risk of bias noted
Suarez 1994
Methods RCT
Participants Participantswithmalignant solid tumours receiving low tomoderately emetogenic agents
only, i.e. single agent or combination therapy with actinomycin, vincristine, methotrex-
ate, cytarabine, etoposide, doxorubicin, daunorubicin, hydroxycarbamide, asparaginase,
bleomycin, and/or vinblastine (n = 23) or highly emetogenic agents, i.e. high doses of
ifosfamide or cyclophosphamide (n = 21)
Excluded if: severe hepatic, renal, or cardiac insufficiency; uncontrolled infection; hyper-
sensitivity or drug allergy; or other current or previous medical condition thatmight con-
found findings or put person at risk. Administration during study of antiemetic agents
other than study drug, neuroleptics, drugs known to induce hepatic enzyme synthesis,
and azole antifungal agents were prohibited
Mean age ~10 years, 37/44 participants male
Interventions (Randomised to 1 of 6 strata: placebo, or tropisetron (0.05, 0.10, 0.20, 0.33, or 0.50 mg/
kg) given as single dose by IV infusion (diluted in normal saline to give volume of 1ml/kg
body weight, administered over 15 minutes immediately before start of chemotherapy)
or, on discharge, orally in small quantity of orange juice for 5, 6, or 7 days when receiving
1 to 3, 4, or 5 days chemotherapy, respectively
Outcomes Daily record cards used by participant/family to record nausea and vomiting (unclear
exactly how)
Notes Tropisetron and matching placebo ampoules were provided by Sandoz Ltd
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk States 2:1 unequal randomisation schedule
Allocation concealment (selection bias) Unclear risk Not stated
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Suarez 1994 (Continued)
Blinding (performance bias and detection
bias)
Acute nausea
Low risk States double-blind. No further details.
Blinding of care provider: yes
Blinding of participant: yes
Blinding of outcome assessors: yes
Blinding (performance bias and detection
bias)
Acute vomiting
Low risk States double-blind. No further details.
Blinding of care provider: yes
Blinding of participant: yes
Blinding of outcome assessors: yes
Blinding (performance bias and detection
bias)
Other outcomes
Low risk States double-blind. No further details.
Blinding of care provider: yes
Blinding of participant: yes
Blinding of outcome assessors: yes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis stated; withdrawals detailed and in-
cluded in analysis
Selective reporting (reporting bias) Unclear risk Grouping of arms apparently post-hoc and driven by the trial
data
Other bias Low risk No other risk of bias noted
Swann 1979
Methods RCT
Cross-over trial but unclear if multiple cross-overs
Participants Any paediatric patient receiving chemotherapy for a malignancy. Age range 2 to 13 years
with 6/18 participants male
Interventions IV metoclopramide (0.5 mg/kg)
IV domperidone (1 mg/kg)
Outcomes Parents or nurses, or both reported nausea and vomiting episodes and duration. Unval-
idated assessment, unclear how undertaken
Notes Data used as though parallel trial
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as “randomised crossover de-
sign”
Allocation concealment (selection bias) Unclear risk Not stated
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Swann 1979 (Continued)
Blinding (performance bias and detection
bias)
Acute nausea
High risk Not reported
Blinding (performance bias and detection
bias)
Acute vomiting
High risk Not reported
Blinding (performance bias and detection
bias)
Other outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated
Selective reporting (reporting bias) Unclear risk Not enough detail to assess




Participants Participants with solid tumour receiving their first (and subsequent) courses of highly
emetogenic (ifos or cyclo > 1 g/m², MTX > 1 g/m², dacarbazine > 100 mg/m², cisplat >
30 mg/m², dox > 45 mg/m², actinoD > 0.3 mg/m², carbo > 150 mg/m²) plus another
agent
Overall mean age 11.5 years (range 2 to 17 years), with 16/30 participants male
Interventions Tropisetron 0.2 mg/kg IV 30 minutes prior to infusion
Chlorpromazine 5 to 15 mg given over 2-hour infusion and 2 further 6-hourly plus
dexamethasone 2 mg/m² IV bolus prior to and at 12 hours




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
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Tejedor 1999 (Continued)
Blinding (performance bias and detection
bias)
Acute nausea
High risk Not reported
Blinding (performance bias and detection
bias)
Acute vomiting
High risk Not reported
Blinding (performance bias and detection
bias)
Other outcomes
Low risk States double-blind. No further details.
Blinding of care provider: yes
Blinding of participant: yes
Blinding of outcome assessors: yes
Incomplete outcome data (attrition bias)
All outcomes
High risk Cross-over with only 50% second-agent completed
Selective reporting (reporting bias) Low risk -




Participants Participants with solid tumour receiving 2 identical courses of cyclo > 1.2 mg/m² or
cisplatin > 90 mg/m². Mean age was 5 years (0.85 to 13 years) with 23/44 episodes in
males
Interventions Granisetron 20 mcg/kg IV prior to chemotherapy
Granisetron 40 mcg/kg IV prior to chemotherapy
Outcomes Unclear who undertook assessment of number of vomiting episodes
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
Acute nausea
High risk Not reported
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Tsuchida 1999 (Continued)
Blinding (performance bias and detection
bias)
Acute vomiting
Unclear risk Not stated
Blinding of care provider: unclear
Blinding of participant: unclear
Blinding of outcome assessors: unclear
Blinding (performance bias and detection
bias)
Other outcomes
High risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk 3 dropouts in higher-dose ondansetron arm - unclear how ac-
counted for; nil in lower-dose arm
Selective reporting (reporting bias) Low risk -
Other bias Low risk No other risk of bias noted
White 2000
Methods RCT
Participants Included people with a variety ofmalignancies excluding primary and secondary tumours
of the CNS, who were to receive moderately to highly emetogenic chemotherapy agents*
given for 1 to 8 days (or interspersed with 1 or 2 single days of no or low emetogenic
chemotherapy - vincristine, thioguanine). 16% had cisplatin
Excluded if: primary and secondary tumours of theCNS;BSA>1.6m², severe concurrent
illness, illness associated with nausea and vomiting, emesis or severe nausea in 24 hours
preceding chemotherapy, receiving antiemetics other than those under investigation (or
in preceding24hours), pregnancy or contraindications to ondansetronor dexamethasone
Mean age 8 years (range 2 to 17 years), 58% of 250 participants male
*These were: cyclophosphamide, doxorubicin or doxorubicin HCL, etoposide, cytara-
bine, methotrexate, ifosfamide, cisplatin, actinomycin D. Doses not reported. (Partici-
pants receiving low emetogenic agents alone were excluded from the analysis.)
Interventions 215 participants were given a loading dose IVI ondansetron 5 mg/m² + oral dexametha-
sone 2 to 4 mg + placebo syrup (20 minutes pre-chemotherapy) then 6 to 8 hours post-
loading dose, oral dexamethasone 2 mg BD if BSA <= 0.6 m², or 4 mg BD if BSA > 0.
6 m². 2 days post-cessation of chemotherapy, oral ondansetron 4 mg syrup BD
223participants were given a loading dose ondansetron syrup 8mg + oral dexamethasone
2 to 4 mg + placebo by IVI (20 minutes pre-chemotherapy) then 6 to 8 hours post-
loading dose, oral dexamethasone 2 mg BD if BSA <= 0.6 m², or 4 mg BD if BSA > 0.
6 m². 2 days post-cessation of chemotherapy, oral ondansetron 4 mg syrup BD
Outcomes Unvalidated nausea and vomiting diary cards completed by parent/guardian, child, or
healthcare staff.Gradednausea as: none, little bit, or very to reflect: none,mild,moderate,
severe
Graded appetite as: none, less than usual, same, more than usual. Episodes of vomiting
recorded
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White 2000 (Continued)
Notes Placebos identical to the oral and IV ondansetron preparations were provided by Glaxo
Wellcome R&D Ltd
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random code
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
Acute nausea
High risk Not reported
Blinding (performance bias and detection
bias)
Acute vomiting
High risk Not reported
Blinding (performance bias and detection
bias)
Other outcomes
Low risk States double-blind. No further details.
Blinding of care provider: yes
Blinding of participant: yes
Blinding of outcome assessors: yes
Incomplete outcome data (attrition bias)
All outcomes
High risk Only 9/250 participants were excluded from analysis, and study
groups were very similar in numbers
Selective reporting (reporting bias) Low risk -
Other bias Low risk No other risk of bias noted
Dosing abbreviations:
BD = twice a day
IV = intravenous
IVI = intravenous infusion
OD = once a day
PO = orally
QDS = four times a day




ABVD = adriamycin, bleomycin, vincristine, dacarbazine
actinoD = actinomycin D
Ara-C = cytarabine
carbo = carboplatin
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ALL = acute lymphoblastic leukaemia
AML = acute myeloid leukaemia
BMT = bone marrow transplant
BSA = body surface area
CNS = central nervous system
MANE = Morrow Assessment of Nausea and Emesis
MRC = Medical Research Council (UK)
NHL = non-Hodgkin’s lymphoma
PD = progressive disease
RCT = randomised controlled trial
Rx = treatment
SA = surface area
TBI = total body irradiation
THC = tetrahydrocannabinol
VAS = visual analogue scale
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aksoylar 2001 ’Day’ randomised rather than participant or episode. Results reported per participant
Alavi 1985 < 18-year-olds not extractable
Basch 2011 Not randomised
Bauduer 1999 < 18-year-olds not extractable
Bonaventura 1999 < 18-year-olds not extractable
Brice 1989 < 18-year-olds not extractable
Corapcioglu 2005 Randomisation not adhered to
Dana 1987 < 18-year-olds not extractable
Delgado 1983 < 18-year-olds not extractable
Fauser 1998 < 18-year-olds not extractable
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(Continued)
Feng 2000 < 18-year-olds not extractable
Feng 2002 < 18-year-olds not extractable
Forni 2000 < 18-year-olds not extractable
Friedman 2000 < 18-year-olds not extractable
Gagen 1984 < 18-year-olds not extractable
Gez 1989 < 18-year-olds not extractable
Gorena 1996 Not randomised
Hatae 1989 Not randomised
Herrstedt 2007 < 18-year-olds not extractable
Hirota 1993a Multiple cross-overs, uncertainly about how randomised the data are, no data to extract parallel or AB/BA
results
Jara 1999 < 18-year-olds not extractable
Joss 1994 < 18-year-olds not extractable
Kearsley 1989 < 18-year-olds not extractable
Keyhanian 2009 Participants not < 18
Koseoglu 1998 Multiple cross-overs, uncertainly about how randomised the data are, no data to extract parallel or AB/BA
results
Luisi 2006 Multiple cross-overs, uncertainly about how randomised the data are, no data to extract parallel or AB/BA
results
Matsuoka 2003 < 18-year-olds not extractable (only 2 participants, 1 in each arm)
Nathan 2006 n-of-1 randomisation
NCT00429702 2007 Terminated without publication of results
Needles 1999 < 18-year-olds not extractable
Onat 1995 < 18-year-olds not extractable
Pillai 2011 < 18-year-olds not extractable
Relling 1993 Multiple courses per randomised participant but without any data to enable cluster or first course assessment
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(Continued)
Roila 1995 < 18-year-olds not extractable
Roila 1996 < 18-year-olds not extractable
Roila 1998 < 18-year-olds not extractable
Roila 2000 < 18-year-olds not extractable
Stiakaki 1999 Multiple courses per randomised participant but without any data to enable cluster or first course assessment
Sumer 1988 Multiple courses per randomised participant but without any data to enable cluster or first course assessment
Tian 2011 Participants not < 18
Tsukuda 2009 Participants not < 18
Yalcin 1999 < 18-year-olds not extractable
Yonemura 2009 Participants not < 18
AB/BA = alternating cross-over trial with each participant receiving either one treatment (A) followed by a second (B), or in the opposite
sequence (B then A)
Characteristics of studies awaiting assessment [ordered by study ID]
Gómez 1995
Methods “un estudio comparativo”, “fueron asignados en forma aleatoria” (Comparative study, random assignment)
Participants “31 pacientes con enfermedad neoplásica recibiendo por primera vez quimioterapia en base a cisplatino (CDDP)
100 mg/m²” (31 participants receiving chemotherapy for the first time based on cisplatin)
“la edad media fue de 43 años (15-69)” (mean 43 years old, range 15 to 69)
Interventions “tropisetron (TROP) 5 mg IV (grupo 1), TROP 5 mg con dexametasona (DEX) 20 mg IV (grupo 2) 10 mg con
DEX 20 mg IV (grupo 3)”
Outcomes “control total del vómito” y “respuesta completa” (Total control of vomiting and the “complete answer”)
Notes Not available via British Library. No web source
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Xu 1997
Methods “a multicenter cooperative study”
Participants 773 participants, no ages given, receiving cisplatin chemotherapy
Interventions “i.v. OND 8 mg once or twice a day”
“i.v. OND 8 mg plus dexamethasone (DXM) 10 mg once a day”
Outcomes Acute and delayed nausea and vomiting
Notes Not available via British Library. No web source
Zeng 1995
Methods “multiple centre, randomized cross-over trial”
Participants “patients receiving non-cisplatin chemotherapy (containing CTX and/or ADM)”
155 participants, no ages given
Interventions Ondansetron (Qilu), metoclopramide or Zofran (Glaxo)
Outcomes Control of acute vomiting, frequency of vomits
Notes Not available via British Library. No web source
Any help in the discovery, translation, and appraisal of these studies would be greatly appreciated.
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D A T A A N D A N A L Y S E S
Comparison 1. Addition of corticosteroids to 5-HT3 antagonists




participants Statistical method Effect size
1 Control of immediate vomiting 2 100 Risk Ratio (Random, 95% CI) 2.03 [1.35, 3.04]
Comparison 2. Granisetron 20 mcg/kg versus 40 mcg/kg




participants Statistical method Effect size
1 Complete control of immediate
vomiting
3 453 Risk Ratio (Fixed, 95% CI) 0.93 [0.80, 1.07]
Comparison 3. Ondansetron vs Granisetron




participants Statistical method Effect size
1 Complete control of acute
nausea
2 101 Risk Ratio (Fixed, 95% CI) 1.05 [0.94, 1.17]
2 Complete control of acute
vomiting
3 167 Risk Ratio (Fixed, 95% CI) 2.26 [2.04, 2.51]
3 Complete control of delayed
nausea
2 101 Risk Ratio (Fixed, 95% CI) 1.13 [0.93, 1.38]
4 Complete control of delayed
vomiting
2 101 Risk Ratio (Fixed, 95% CI) 1.13 [0.98, 1.29]
Comparison 4. Other antiemetic comparisons




participants Statistical method Effect size
1 Complete control of acute
nausea
Other data No numeric data
2 Complete control of acute
vomiting
Other data No numeric data
3 Complete control of delayed
vomiting
Other data No numeric data
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4 Complete control of acute
nausea and vomiting
Other data No numeric data
5 Other nausea &/or vomiting
outcomes
Other data No numeric data
Analysis 1.1. Comparison 1 Addition of corticosteroids to 5-HT3 antagonists, Outcome 1 Control of
immediate vomiting.
Review: Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood
Comparison: 1 Addition of corticosteroids to 5-HT3 antagonists







alone log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Hirota 1993 20 20 0.470004 (0.223607) 43.3 % 1.60 [ 1.03, 2.48 ]
Alvarez 1995 30 30 0.887303 (0.163299) 56.7 % 2.43 [ 1.76, 3.34 ]
Total (95% CI) 50 50 100.0 % 2.03 [ 1.35, 3.04 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 2.27, df = 1 (P = 0.13); I2 =56%
Test for overall effect: Z = 3.42 (P = 0.00063)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours 5HT3 antagonist Favours added steroid
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Analysis 2.1. Comparison 2 Granisetron 20 mcg/kg versus 40 mcg/kg, Outcome 1 Complete control of
immediate vomiting.
Review: Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood
Comparison: 2 Granisetron 20 mcg/kg versus 40 mcg/kg
Outcome: 1 Complete control of immediate vomiting
Study or subgroup Granisitron 20mcg/kg
Granisitron
40mcg/kg log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Komada 1999 36 36 -0.15906 (0.220479) 11.0 % 0.85 [ 0.55, 1.31 ]
Tsuchida 1999 44 43 -0.09995 (0.165879) 19.5 % 0.90 [ 0.65, 1.25 ]
Mabro 2000 143 151 -0.05345 (0.087879) 69.5 % 0.95 [ 0.80, 1.13 ]
Total (95% CI) 223 230 100.0 % 0.93 [ 0.80, 1.07 ]
Heterogeneity: Chi2 = 0.23, df = 2 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours 40mcg/kg Favours 20mcg/kg
Analysis 3.1. Comparison 3 Ondansetron vs Granisetron, Outcome 1 Complete control of acute nausea.
Review: Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood
Comparison: 3 Ondansetron vs Granisetron
Outcome: 1 Complete control of acute nausea
Study or subgroup Granisetron Ondansetron log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Noguera 2001 12 29 0.0121 (0.0695) 65.2 % 1.01 [ 0.88, 1.16 ]
Siddique 2011 30 30 0.1133 (0.0951) 34.8 % 1.12 [ 0.93, 1.35 ]
Total (95% CI) 42 59 100.0 % 1.05 [ 0.94, 1.17 ]
Heterogeneity: Chi2 = 0.74, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours ondansetron Favours granisetron
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Analysis 3.2. Comparison 3 Ondansetron vs Granisetron, Outcome 2 Complete control of acute vomiting.
Review: Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood
Comparison: 3 Ondansetron vs Granisetron
Outcome: 2 Complete control of acute vomiting
Study or subgroup Granisetron Ondansetron log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Jaing 2004 33 33 0.2877 (0.2368) 4.8 % 1.33 [ 0.84, 2.12 ]
Noguera 2001 12 29 1 (0.0603) 74.7 % 2.72 [ 2.42, 3.06 ]
Siddique 2011 30 30 0.2763 (0.1152) 20.5 % 1.32 [ 1.05, 1.65 ]
Total (95% CI) 75 92 100.0 % 2.26 [ 2.04, 2.51 ]
Heterogeneity: Chi2 = 36.24, df = 2 (P<0.00001); I2 =94%
Test for overall effect: Z = 15.68 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours ondansetron Favours granisetron
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Analysis 3.3. Comparison 3 Ondansetron vs Granisetron, Outcome 3 Complete control of delayed nausea.
Review: Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood
Comparison: 3 Ondansetron vs Granisetron
Outcome: 3 Complete control of delayed nausea
Study or subgroup Granisetron Ondansetron log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Noguera 2001 12 29 -0.1109 (0.1386) 53.0 % 0.90 [ 0.68, 1.17 ]
Siddique 2011 30 30 0.3878 (0.1472) 47.0 % 1.47 [ 1.10, 1.97 ]
Total (95% CI) 42 59 100.0 % 1.13 [ 0.93, 1.38 ]
Heterogeneity: Chi2 = 6.08, df = 1 (P = 0.01); I2 =84%
Test for overall effect: Z = 1.22 (P = 0.22)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours ondansetron Favours granisetron
Analysis 3.4. Comparison 3 Ondansetron vs Granisetron, Outcome 4 Complete control of delayed vomiting.
Review: Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood
Comparison: 3 Ondansetron vs Granisetron
Outcome: 4 Complete control of delayed vomiting
Study or subgroup Granisetron Ondansetron log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Noguera 2001 12 29 0.0478 (0.0781) 75.7 % 1.05 [ 0.90, 1.22 ]
Siddique 2011 30 30 0.3365 (0.138) 24.3 % 1.40 [ 1.07, 1.83 ]
Total (95% CI) 42 59 100.0 % 1.13 [ 0.98, 1.29 ]
Heterogeneity: Chi2 = 3.31, df = 1 (P = 0.07); I2 =70%
Test for overall effect: Z = 1.73 (P = 0.083)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours ondansetron Favours granisetron
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Analysis 4.1. Comparison 4 Other antiemetic comparisons, Outcome 1 Complete control of acute nausea.
Complete control of acute nausea












m² IV over 15
minutes immedi-
ately prior to che-
motherapy,
then at +8 hours
and +16. Ongo-
ing ondansetron
given orally < 1
m² 4 mg TDS, >
1 m² 8 mg TDS,
continued for 3
days after last day
of chemotherapy





m² IV over 15
minutes immedi-
ately prior to che-
motherapy, then




given orally < 1
m² 4 mg TDS, >
1 m² 8 mg TDS,
continued for 3
days after last day
of chemotherapy
or 5 days if nau-
sea and vomiting
persisted




m², given at -






(for < 0.7 m² pa-
tients) or 10 mg
(for > 0.7 m² pa-
tients) at -2, 8,
16 and 24 hours.
Placebo given at
+4 hours




m2, given at -








(SA) 0.7 to 1.1
m²20mg/day di-
vided, SA 1.1 to
1.4 m² 30 mg/
day divided, SA
> 1.1 m² 40 mg/
day divided
18 episodes 18 episodes 20.7 17.2 to 36.2
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0.5 mg/kg IV 30
minutes prior to
chemotherapy









29 episodes 20 episodes 0.97 0.54 to 1.69
Sandoval 1999 Ondansetron 0.
6 mg/kg (max






8 mg) IV over
30 minutes be-
fore chemother-
apy then every 4
hours for a total
of 4 doses







1 to 0.4 mg/kg)
given as single
dose
26 patients 18 patients 0.98 0.54 to 1.74
Analysis 4.2. Comparison 4 Other antiemetic comparisons, Outcome 2 Complete control of acute
vomiting.
Complete control of acute vomiting





























apy, then BD on
chemo for 1 to 5
days
30 episodes 30 episodes 2.43 1.76 to 3.34
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Complete control of acute vomiting (Continued)
Basade 1996 Dexametha-




1.5 mg/kg IV 15
minutes prior to
chemotherapy
53 episodes 52 episodes 2.10 1.77 to 2.50
Berrak 2007 Granisetron




40 mcg/kg IV 30
minutes prior to
Rx
104 episodes 121 episodes 0.88 0.70 to 1.10
Brock 1996 On-
dansetron 5 mg/
m² IV over 15
minutes immedi-
ately prior to che-
motherapy,
then at +8 hours
and +16. Ongo-
ing ondansetron
given orally < 1
m² 4 mg TDS, >
1 m² 8 mg TDS,
continued for 3
days after last day
of chemotherapy





m² IV over 15
minutes immedi-
ately prior to che-
motherapy, then




given orally < 1
m² 4 mg TDS, >
1 m² 8 mg TDS,
continued for 3
days after last day
of chemotherapy
or 5 days if nau-
sea and vomiting
persisted
79 patients 79 patients 0.89 0.72 to 1.10
Chan 1987 Nabilone orally
(capsules) start-










to 12 hours prior
to chemotherapy
and repeated 2
or 3 times a
day according to
dosage schedule
30 episodes 30 episodes 1.00 0.85 to 1.17





orally for 3 days
Metoclo-
pramide 10 mg/
m² IV QDS for





m² TDS IV or
15 patients 15 patients 3.67 2.25 to 5.98
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m², given at -






(for < 0.7 m² pa-
tients) or 10 mg
(for > 0.7 m² pa-
tients) at -2, 8,
16 and 24 hours.
Placebo given at
+4 hours




m², given at -








to 1.1 m² 20 mg/
day divided, SA
1.1 to 1.4 m² 30
mg/day divided,
SA > 1.1 m² 40
mg/day divided
18 episodes 18 episodes 19.00 13.71 to 26.33
Hirota 1993 Granisetron








40 mcg/kg IV 30
minutes prior to
Rx
20 episodes 20 episodes 1.60 1.03 to 2.48
Marshall 1989 Cocktail. Meto-
clo-
pramide 2 mg/
kg/dose 0, 2, 6,
12 hours. Dex 0.
7 mg/kg 0 hours.
Benztropine
0.02 mg/kg/dose
0, 6 hours. Lo-
razepam
0.05 mg/kg/dose
-1 hour and 12











0.5 mg/kg IV 30
minutes prior to
10 patients 10 patients 1.00 0.54 to 1.86
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Complete control of acute vomiting (Continued)
prior to chemo chemotherapy
Parker 2001 Placebo (saline)
IV 15-minute in-
fusion 30 min-









51 episodes 47 episodes 0.51 0.38 to 0.69
Safonova 1999 Ondansetron 8
mg PO BD plus




m² IV BD plus 4
to 8 mg dexam-
ethasone IV
26 patients 26 patients 1.04 0.62 to 1.75
Sandoval 1999 Ondansetron 0.
6 mg/kg (max






8 mg) IV over
30 minutes be-
fore chemother-
apy then every 4
hours for a total
of 4 doses







1 to 0.4 mg/kg)
given as single
dose
23 patients 18 patients 0.89 0.51 to 1.54
Analysis 4.3. Comparison 4 Other antiemetic comparisons, Outcome 3 Complete control of delayed
vomiting.
Complete control of delayed vomiting















40 mcg/kg IV 30
minutes prior to
Rx
18 episodes 18 episodes 1.07 0.94 to 1.21
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Analysis 4.4. Comparison 4 Other antiemetic comparisons, Outcome 4 Complete control of acute nausea
and vomiting.
Complete control of acute nausea and vomiting
















orally for 3 days
Metoclo-
pramide 10 mg/
m² IV QDS for
3 days, with 2.
5 mg procycli-
dineDexametha-
sone 4 mg/m² IV
then 2 mg/m²
TDS IV or PO
15 patients 15 patients 3.67 2.25 to 5.98
Mabro 2000 20 µg/kg oral
granisetron (or-
ange flavoured)
given 1 hour be-





given 1 hour be-
fore and again 6
to 12 hours
143 patients 151 patients 0.96 0.82 to 1.14
Sandoval 1999 Ondansetron 0.
6 mg/kg (max






8 mg) IV over
30 minutes be-
fore chemother-
apy then every 4
hours for a total
of 4 doses
16 patients 15 patients 1.25 0.70 to 2.23
Tejedor 1999 Tropisetron





15 mg given over
2-hour infusion




prior to and at12
hours
44 episodes 43 episodes 1.03 0.79 to 1.35
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Analysis 4.5. Comparison 4 Other antiemetic comparisons, Outcome 5 Other nausea &/or vomiting
outcomes.
Other nausea &/or vomiting outcomes




















Dalzell 1986 Nabilone 0.5
mg BD if < 18
kg, 1 mg BD
if 18 to 36 kg,
1mg TDS if >
36 kg
Domperidone
5 mg TDS if <
18 kg, 10 mg
TDS if 18 to
36 kg, 15 mg
TDS if > 36 kg
18 episodes 18 episodes 1.5 2.5 Mean severity
score (0 =
nil, 3 = worst)

























46 patients 42 patients 1.5 7 Median num-
ber of vomits
in first 24hrs,
















































sea score (0 =
nil, 5 = worst)
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A D D I T I O N A L T A B L E S
Table 1. Adverse events - 5-HT3 antagonists
Citation Adverse events noted
Alvarez 1995 Not shown separately by intervention. Overall mild-moderate sedation 49%, restlessness 29%, headache
17%, diarrhoea 17%, and hiccups 2%
Berrak 2007 None reported in either group (granisetron 10 mcg/kg or 40 mcg/kg)
Brock 1996 Ondansetron 5 mg/m²: 2 almost certainly related: headache and dizziness. 2 probably related: headache
and warm feeling
Ondansetron 10 mg/m²: 1 probably related: headache
Dick 1995 Ondansetron: leg pains (1)
Hahlen 1995 Granisetron:
• Somnolence (2)
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Table 1. Adverse events - 5-HT3 antagonists (Continued)
• Fever (not considered related to primary disease) (8)
• Mild- to moderate-severity headache of short duration (8)
• Abdominal pain (not thought to be related to primary disease) (8)
• Leukopenia (7)
Hirota 1993 None reported
Jaing 2004 Numbers not specified. Adverse effects same in each group: mild headache and constipation
Komada 1999 No side effects related to the study medication
Mabro 2000 20 µg/kg granisetron: headache 8 (6%), constipation 9 (6%), deranged liver enzymes 8 (6%)
40 µg/kg granisetron: headache 14 (9%), constipation 6 (4%), deranged liver enzymes 7 (5%)
Mehta 1997 Ondansetron: headaches (8), mild to moderate sedation (10)
Noguera 2001 Numbers not given or specified by antiemetic - “rare” and “low intensity”
Orchard 1999 Not reported separately for children
Safonova 1999 None recorded
Sandoval 1999 “No patients suffered clinical or laboratory toxicity”
Sepulveda-Vildosola 2008 “None of the patients reported or presented any adverse effect”
Siddique 2011 “Adverse effects like headache, constipation, abdominal pain and loose motion were common in both
group of children but their number was much less in children who received granisetron” [compared with
ondansetron]
Suarez 1994 Placebo or tropisetron 0.05 mg/kg: anxiety (9), headache (5), abdominal pain (4), sweating (2), and 1
each of hypertension, diarrhoea, fever, and fall
Tropisetron 0.10 to 0.50 mg/kg: headache (3), tremor (3), rash (3), muscle pain (2), 1 each of vertigo
and fatigue
Tejedor 1999 Tropisetron: hypertension (1), abdominal pain (5), constipation (2), headache (2), headache anddizziness
(1)
White 2000 Granisetron 20 mcg/kg. Most commonly reported: abdominal/gastrointestinal discomfort and pain 4%,
fever/pyrexia 3%, diarrhoea and headaches 2%
Granisetron 40 mcg/kg. Most commonly reported: abdominal/gastrointestinal discomfort and pain 3%,
fever/pyrexia 3%, diarrhoea and headaches 2%
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Table 2. Adverse events - cannabinoids
Citation Adverse events noted
Chan 1987 Nabilone orally: dizziness (18), drowsiness (24), mood alteration (5), ocular swelling and irritation (4), orthostatic
hypotension (3), muscle twitching (2), increased appetite (1)
Dalzell 1986 Nabilone: hallucinations requiring withdrawal from trial (1), drowsiness (12), dizziness (8), mood changes (3), pruritis
(1), dry mouth (1), vagueness (1), light-headedness (1), increased appetite (1)
Ekert 1979 Tetrahydrocannabinol: drowsiness (4)
Ekert 1979a Tetrahydrocannabinol: drowsiness (6), mood alteration (2)
Table 3. Adverse events - other agents
Citation Adverse events noted
Basade 1996 Dexamethasone: insomnia (1), depression (1), anorexia (1), abdominal pain (1)
Metoclopramide: dystonia (1), depression (3), anorexia (4), abdominal pain (2), headache (1)
Chan 1987 Prochlorperazine orally: dizziness (1), drowsiness (6), mood alteration (4), ocular swelling and irritation (1),
muscle twitching (1)
Dalzell 1986 Domperidone: drowsiness (6), dizziness (1), mood changes (1), pruritis (1)
Dick 1995 Metoclopramide and dexamethasone: stomach aches (2), agitation/behaviour (2), tiredness (1)
Ekert 1979 Metoclopramide: drowsiness (2)
Ekert 1979a Prochlorperazine: none recorded
Emir 2013 Cocktail: granisetron, dexamethasone, midazolam, and diphenhydramine: constipation (2), sedation (4), hy-
potension (2)
Graham-Pole 1986 Metoclopramide: extrapyramidal side effects (5/24), somnolence (2/24)
Chlorpromazine: extrapyramidal side effects (1/26), somnolence (14/26)
Hahlen 1995 Dexamethasone:
• Somnolence - remained a problem after dose reduction (severe in 7/19) (19)
• Fever (8)
• Headache (5)
• Abdominal pain (5)
• Leukopenia (5)
• Extrapyramidal reactions (severe ocular-buccal dyskinesia, moderate choreoathetosis) (2)
Kurucu 2012 Hydroxyzine: side effects in 14 participants in control (ondansetron) and 10 participants in (ondansetron plus)
hydroxyzine group, consisting of constipation, headache, and dry mouth
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Table 3. Adverse events - other agents (Continued)
Marshall 1989 Chlorpromazine: diarrhoea (3)
Cocktail.Metoclopramide, dexamethasone, benzatropine, and lorazepam: diarrhoea (2), dystonia (1), akasthasia
(2)
Mehta 1986 Chlorpromazine: sedation (7)
Methylprednisolone: sedation (3)
Mehta 1997 Perphenazine plus diphenhydramine: dystonia (2), mild to moderate sedation (24)
Swann 1979 Metoclopramide or domperidone. Followed up at 3-weekly intervals: no adverse effects, no unanticipated
change in blood count, no deaths, no clinical evidence of jaundice
Tejedor 1999 Chlorpromazine plus dexamethasone: abdominal pain (2), somnolence (2), headaches (7)
A P P E N D I C E S
Appendix 1. Search strategies for medical databases
Search used in CENTRAL/The Cochrane Library
#1 MeSH descriptor Benzodiazepines explode all trees
#2 (Alprazolam or Alprazolan or alprox or esparon or apo-alpraz or apoalpraz or cassadan or d-65mt or d65mt or kalma or novo-
alprazol or novoalprazol or nu-alpraz or nualpraz or ralozam or u-31,889 or u31,889 or xanax or tafil or trankimazin or Niravam)
#3 (Anthramycin or antramycin)
#4 (Bromazepam or anxyrex or apo-bromazepam or bromalich or bromaz or bromazanil or bromazep or lexotan or lexomil or
lexotanil or lexatin or ro 5-3350 or ro 53350 or durazanil or gen-bromazepam)
#5 (Clonazepam or antelepsin or rivotril or ro 5-4023 or ro 54023 or klonopin)
#6 (Devazepide or mk-329 or mk329)
#7 (Diazepam or apaurin or diazemuls or faustan or relanium or seduxen or sibazon or stesolid or valium or rimapam or tensium
or dialar or valclair or diastat or dizac or q-pam or valrelease)
#8 (Nordazepam or demethyldiazepam or desmethyldiazepam or deoxydemoxepam or nordiazepam or norprazepam or dealkyl-
prazepam or calmday or nordaz or tranxilium n or vegesan)
#9 (Flumazenil or flumazepil or romazicon or anexate or lanexat or ro 15-1788 or ro 151788 or Anexate)
#10 (Lorazepam or apo-lorazepam or apolorazepam or ativan or orfidal or temesta or donix or duralozam or durazolam or idalprem
or laubeel or lorazep von ct or novo-lorazem or novolorazem or nu-loraz or nuloraz or sedicepan or sinestron or somagerol or tolid or
wy-4036 or wy4036 or loraz)
#11 (Flunitrazepamor fluridrazepamor flunitrazepam-teva or flunizep von ct or ro-5-4200 or ro54200 or flunimerck or flunitrazepam-
neuraxpharm or flunitrazepam-ratiopharm or fluninoc or rohypnol or narcozep or rohipnol or flunibeta)
#12 (Flurazepam or dalmane or Dormodor or dalmadorm or staurodorm or apo-flurazepam)
#13 (Nitrazepam or Nitrodiazepam or alodorm or dormalon or dormo-puren or eatan or imadorm or imeson or mogadon or
nitrazadon or nitrazep or novanox or radedorm or remnos or rhoxal-nitrazepam or serenade or somnite)
#14 (Oxazepam or adumbran or serax or tazepam)
#15 (Pirenzepine or pirenzepin or pyrenzepine or ulcoprotect or ulgescum or gastrotsepin or piren-basan or pirenzepin-ratiopharm
or gastrozepin)
82Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
#16 (Prazepam or centrax or demetrin or lysanxia or reapam)
#17 (Temazepam or 3-hydroxydiazepam or hydroxydiazepam or methyloxazepam or oxydiazepam or pronervon t or remestan or
restoril or ro-5-5345 or ro55345 or sah 47-603 or sah 47603 or apo-temazepam or euhypnos or planum or levanxol or pms-temazepam
or nu-temazepam or novo-temazepam or nortem or normitab or normison or nocturne or temtabs or gen-temazepam or dasuen or
signopam or temaze or temazep von ct or tenox or wy-3917 or wy3917 or temaz)
#18 (Chlordiazepoxide or methaminodiazepoxide or chlozepid or elenium or librium or a-poxide or chlordiazachel or librelease or
libritabs or lygen)
#19 (Chlorazepate or tranxene or tranxilium)
#20 (Estazolam or nuctalon or prosom or tasedan)
#21 (Medazepam or nobrium or ro 5-4556 or ro 54556 or rudotel or rusedal)
#22 (Midazolam or dormicum or ro 21-3981 or ro 213981 or versed or hypnovel)
#23 (Triazolam or apo-triazo or gen-triazolam or halcyon or halcion or trilam)
#24 MeSH descriptor Cannabinoids explode all trees
#25 (cannabinoid* or canabinoid* or Tetrahydrocannabinol or thc or marinol or nabilone or cesamet)
#26 (#25 OR #26)
#27 MeSH descriptor Beclomethasone, this term only
#28 (Beclomethasone or beclometasone or qvar or aerobec forte or beclazone or ecobec or filair or aerobec or nasobec aqueous or
prolair or respocort or ventolair or vancenase or vanceril or aldecin or viarin or apo-beclomethasone or ascocortonyl or beclamet or
beclocort or beclomet or beclorhinol or becloturmant or sanasthmax or beclovent or beconase or propaderm or sanasthmyl or becodisks
or becotide or becloforte or bronchocort or junik or asmabec clickhaler or beclazone or clenil modulate)
#29 MeSH descriptor Betamethasone, this term only
#30 (Betamethasone or betadexamethasone or flubenisolone or celeston or celestona or celestone or cellestoderm or Betnelan or
betnesol)
#31 MeSH descriptor Betamethasone 17-Valerate, this term only
#32 (betamethasone 17-valerate or flubenisolonvalerate or betnovate or Beta-val or betaderm or betatrex or dermabet or luxiq or
valisone or valnac or betacap or betamethasone valerate or bettamousse or diprosone)
#33 MeSH descriptor Budesonide, this term only
#34 (Budesonide or horacort or pulmicort or rhinocort or novolizer or entocort)
#35 MeSH descriptor Dexamethasone, this term only
#36 (Dexamethasone or hexadecadrol or methylfluorprednisolone or dexpak or maxidex or decaject or decameth or decaspray or
dexasone or hexadrol or millicorten or oradexon or aeroseb-dex or decaderm dexamethasone or decadron or decadron or mymethasone)
#37 MeSH descriptor Dexamethasone Isonicotinate, this term only
#38 (dexamethasone isonicotinate or auxison)
#39 MeSH descriptor Flumethasone, this term only
#40 (Flumethasone or fluorodexamethasone or locorten)
#41 MeSH descriptor Fluorometholone, this term only
#42 (Fluorometholone or cortisdin or flucon or fluoro-ophtal or fml or pms-fluorometholone or fluoropos or oxylone)
#43 MeSH descriptor Fluprednisolone, this term only
#44 (fluprednisolone or alphadrol)
#45 MeSH descriptor Flurandrenolone, this term only
#46 (Flurandrenolone or flurandrenolide or cordran or haelan or fludroxycortide)
#47 MeSH descriptor Melengestrol Acetate, this term only
#48 (melengestrol acetate or melengestrol)
#49 MeSH descriptor Methylprednisolone, this term only
#50 (Methylprednisolone or metipred or medrol or urbason or medrone or solu-medrone or depo-medrone)
#51 MeSH descriptor Methylprednisolone Hemisuccinate, this term only
#52 (a-methapred or solu-medrol or solumedrol or urbason-soluble or urbasonsoluble)
#53 MeSH descriptor Prednisolone, this term only
#54 (Prednisolone or di-adreson-f or diadresonf or predate or predonine or cortalone or delta-cortef or fernisolone-p or meti-derm
or prelone or sterane)
#55 MeSH descriptor Prednisone, this term only
#56 (Prednisone or dehydrocortisone or delta-cortisone or prednison galen or prednison hexal or pronisone or rectodelt or apo-
prednisone or cortancyl or panafcort or dacortin or deltasone or prednidib or predni tablinen or panasol or orasone or meticorten or
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liquid pred or kortancyl or enkortolon or encortone or encorton or prednison acsis or predniment or decortisyl or cutason or cortan
or winpred or ultracorten or sone or sterapred or delta-dome or fernisone or paracort or predincen-m or servisone)
#57 MeSH descriptor Cyclizine, this term only
#58 (Cyclizine or marezine or valoid)
#59 (#59 OR #60)
#60 MeSH descriptor Chlorpromazine, this term only
#61 (Chlorpromazine or propaphenin or aminazine or chlordelazine or contomin or largactil or fenactil or chlorazine or thorazine
or thorazine)
#62 MeSH descriptor Domperidone, this term only
#63 (Domperidone or domperidon or apo-domperidone or domidon or domperidon-teva or gastrocure or motilium or nauzelin or
novo-domperidone or nu-domperidone or pms-domperidone or peridys or ratio-domperidone)
#64 MeSH descriptor Droperidol, this term only
#65 (Droperidol or dehydrobenzperidol or droleptan or dehidrobenzperidol or inapsine or inapsine)
#66 MeSH descriptor Haloperidol, this term only
#67 (Haloperidol or haldol or dozic or serenace)
#68 MeSH descriptor Methotrimeprazine, this term only
#69 (Methotrimeprazine or levomeprazin or levopromazine or levomepromazine or tisercin or tizertsin or tizercine or levoprome or
nozinan)
#70 MeSH descriptor Metoclopramide, this term only
#71 (Metoclopramide or metaclopramide or metaclopromide or cerucal or maxolon or primperan or raglan or rimetin)
#72 MeSH descriptor Perphenazine, this term only
#73 (Perphenazine or chlorpiprazine or perfenazine or trilafon or fentazin)
#74 MeSH descriptor Prochlorperazine, this term only
#75 (Prochlorperazine or compazine or stemetil or buccastem or compro)
#76 MeSH descriptor Trifluoperazine, this term only
#77 (Trifluoperazine or trifluoroperazine or trifluperazine or stelazine or triftazin or apo-trifluoperazine or apotrifluoperazine or
eskazine or flupazine or terfluzine)
#78 MeSH descriptor Granisetron, this term only
#79 MeSH descriptor Ondansetron, this term only
#80 (granisetron):ti or (granisetron):ab
#81 (odansetron or ondansetron):ti or (odansetron or ondansetron):ab
#82 (tropisetron):ti or (tropisetron):ab
#83 (dolasetron):ti or (dolasetron):ab
#84 (anzemet):ti or (anzemet):ab
#85 (kytril or Eutrom or Kevatril or Taraz):ti or (kytril or Eutrom or Kevatril or Taraz):ab
#86 (zofran or Zofrene or Zophran or Zophren or Avessa or Ceramos):ti or (zofran or Zofrene or Zophran or Zophren or Avessa or
Ceramos):ab
#87 (5-HT3 antagonist*):ti or (5-HT3 antagonist*):ab
#88 (5-HT3 blocker*):ti or (5-HT3 blocker*):ab
#89 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or
#20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #
38 or #39 or #40 or #41 or #42 or #43 or #44 or #45 or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56
or #57 or #58 or #59 or #60 or #61 or #62 or #63 or #64 or #65 or #66 or #67 or #68 or #69 or #70 or #71 or #72 or #73 or #74 or
#75 or #76 or #77 or #78 or #79 or #80 or #81 or #82 or #83 or #84 or #85 or #86 or #87 or #88
#90 (infant OR infan* OR newborn OR newborn* OR new-born* OR baby OR baby* OR babies OR neonat* OR child OR child*
OR schoolchild* OR schoolchild OR school child OR school child* OR kid OR kids OR toddler* OR adolescent OR adoles* OR
teen* OR boy* OR girl* ORminors ORminors* OR underag* OR under ag* OR juvenil* OR youth* OR kindergar* OR puberty OR
puber* OR pubescen* OR prepubescen* OR prepuberty* OR pediatrics OR pediatric* OR paediatric* OR peadiatric* OR schools OR
nursery school* OR preschool* OR pre school* OR primary school* OR secondary school* OR elementary school* OR elementary
school OR high school* OR highschool* OR school age OR schoolage OR school age* OR schoolage* OR infancy)
#91 MeSH descriptor Nausea, this term only
#92 (nausea)
#93 MeSH descriptor Vomiting, this term only
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#98 (#91 OR #92 OR #93 OR #94 OR #95 OR #96 OR #97)









#108 (leukemia or leukaemia)
#109 (chemotherap$)
#110 #99 or #100 or #101 or #102 or #103 or #104 or #105 or #106 or #107 or #108 or #109
#111 #89 and #90 and #98 and #110
[$= zero or many characters; ti=title; ab=abstract]
All databases were searched
Search used in MEDLINE/OVID and MEDLINE In-process/OVID
1. exp Benzodiazepines/
2. (Alprazolam or Alprazolan or alprox or esparon or apo-alpraz or apoalpraz or cassadan or d-65mt or d65mt or kalma or novo-
alprazol or novoalprazol or nu-alpraz or nualpraz or ralozam or u-31,889 or u31,889 or xanax or tafil or trankimazin or Niravam).ti,ab.
3. (Anthramycin or antramycin).ti,ab.
4. (Bromazepam or anxyrex or apo-bromazepam or bromalich or bromaz or bromazanil or bromazep or lexotan or lexomil or
lexotanil or lexatin or ro 5-3350 or ro 53350 or durazanil or gen-bromazepam).ti,ab.
5. (Clonazepam or antelepsin or rivotril or ro 5-4023 or ro 54023 or klonopin).ti,ab.
6. (Devazepide or mk-329 or mk329).ti,ab.
7. (Diazepam or apaurin or diazemuls or faustan or relanium or seduxen or sibazon or stesolid or valium or rimapam or tensium
or dialar or valclair or diastat or dizac or q-pam or valrelease).ti,ab.
8. (Nordazepam or demethyldiazepam or desmethyldiazepam or deoxydemoxepam or nordiazepam or norprazepam or dealkyl-
prazepam or calmday or nordaz or tranxilium n or vegesan).ti,ab.
9. (Flumazenil or flumazepil or romazicon or anexate or lanexat or ro 15-1788 or ro 151788 or Anexate).ti,ab.
10. (Lorazepam or apo-lorazepam or apolorazepam or ativan or orfidal or temesta or donix or duralozam or durazolam or idalprem
or laubeel or lorazep von ct or novo-lorazem or novolorazem or nu-loraz or nuloraz or sedicepan or sinestron or somagerol or tolid or
wy-4036 or wy4036 or loraz).ti,ab.
11. (Flunitrazepamor fluridrazepamor flunitrazepam-teva or flunizep von ct or ro-5-4200or ro54200 or flunimerck or flunitrazepam-
neuraxpharm or flunitrazepam-ratiopharm or fluninoc or rohypnol or narcozep or rohipnol or flunibeta).ti,ab.
12. (Flurazepam or dalmane or Dormodor or dalmadorm or staurodorm or apo-flurazepam).ti,ab.
13. (Nitrazepam or Nitrodiazepam or alodorm or dormalon or dormo-puren or eatan or imadorm or imeson or mogadon or
nitrazadon or nitrazep or novanox or radedorm or remnos or rhoxal-nitrazepam or serenade or somnite).ti,ab.
14. (Oxazepam or adumbran or serax or tazepam).ti,ab.
15. (Pirenzepine or pirenzepin or pyrenzepine or ulcoprotect or ulgescum or gastrotsepin or piren-basan or pirenzepin-ratiopharm
or gastrozepin).ti,ab.
16. (Prazepam or centrax or demetrin or lysanxia or reapam).ti,ab.
17. (Temazepam or 3-hydroxydiazepam or hydroxydiazepam or methyloxazepam or oxydiazepam or pronervon t or remestan or
restoril or ro-5-5345 or ro55345 or sah 47-603 or sah 47603 or apo-temazepam or euhypnos or planum or levanxol or pms-temazepam
or nu-temazepam or novo-temazepam or nortem or normitab or normison or nocturne or temtabs or gen-temazepam or dasuen or
signopam or temaze or temazep von ct or tenox or wy-3917 or wy3917 or temaz).ti,ab.
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18. (Chlordiazepoxide or methaminodiazepoxide or chlozepid or elenium or librium or a-poxide or chlordiazachel or librelease or
libritabs or lygen).ti,ab.
19. (Chlorazepate or tranxene or tranxilium).ti,ab.
20. (Estazolam or nuctalon or prosom or tasedan).ti,ab.
21. (Medazepam or nobrium or ro 5-4556 or ro 54556 or rudotel or rusedal).ti,ab. (216)
22. (Midazolam or dormicum or ro 21-3981 or ro 213981 or versed or hypnovel).ti,ab.
23. (Triazolam or apo-triazo or gen-triazolam or halcyon or halcion or trilam).ti,ab.
24. or/1-23
25. exp Cannabinoids/
26. (cannabinoid$ or canabinoid$ or Tetrahydrocannabinol or thc or marinol or nabilone or cesamet).ti,ab.
27. 25 or 26
28. Beclomethasone/
29. (Beclomethasone or beclometasone or qvar or aerobec forte or beclazone or ecobec or filair or aerobec or nasobec aqueous or
prolair or respocort or ventolair or vancenase or vanceril or aldecin or viarin or apo-beclomethasone or ascocortonyl or beclamet or
beclocort or beclomet or beclorhinol or becloturmant or sanasthmax or beclovent or beconase or propaderm or sanasthmyl or becodisks
or becotide or becloforte or bronchocort or junik or asmabec clickhaler or beclazone or clenil modulate).ti,ab.
30. Betamethasone/
31. (Betamethasone or betadexamethasone or flubenisolone or celeston or celestona or celestone or cellestoderm or Betnelan or
betnesol).ti,ab.
32. betamethasone 17-valerate/
33. (betamethasone 17-valerate or flubenisolonvalerate or betnovate or Beta-val or betaderm or betatrex or dermabet or luxiq or
valisone or valnac or betacap or betamethasone valerate or bettamousse or diprosone).ti,ab.
34. Budesonide/
35. (Budesonide or horacort or pulmicort or rhinocort or novolizer or entocort).ti,ab.
36. Dexamethasone/
37. (Dexamethasone or hexadecadrol or methylfluorprednisolone or dexpak or maxidex or decaject or decameth or decaspray or
dexasone or hexadrol or millicorten or oradexon or aeroseb-dex or decaderm dexamethasone or decadron or decadron or mymetha-
sone).ti,ab.
38. dexamethasone isonicotinate/
39. (dexamethasone isonicotinate or auxison).ti,ab.
40. flumethasone/
41. (Flumethasone or fluorodexamethasone or locorten).ti,ab.
42. Fluorometholone/
43. (Fluorometholone or cortisdin or flucon or fluoro-ophtal or fml or pms-fluorometholone or fluoropos or oxylone).ti,ab.
44. fluprednisolone/
45. (fluprednisolone or alphadrol).ti,ab.
46. Flurandrenolone/
47. (Flurandrenolone or flurandrenolide or cordran or haelan or fludroxycortide).ti,ab.
48. melengestrol acetate/
49. (melengestrol acetate or melengestrol).ti,ab.
50. Methylprednisolone/
51. (Methylprednisolone or metipred or medrol or urbason or medrone or solu-medrone or depo-medrone).ti,ab.
52. methylprednisolone hemisuccinate/
53. (a-methapred or solu-medrol or solumedrol or urbason-soluble or urbasonsoluble).ti,ab.
54. Prednisolone/
55. (Prednisolone or di-adreson-f or diadresonf or predate or predonine or cortalone or delta-cortef or fernisolone-p or meti-derm
or prelone or sterane).ti,ab.
56. Prednisone/
57. (Prednisone or dehydrocortisone or delta-cortisone or prednison galen or prednison hexal or pronisone or rectodelt or apo-
prednisone or cortancyl or panafcort or dacortin or deltasone or prednidib or predni tablinen or panasol or orasone or meticorten or
liquid pred or kortancyl or enkortolon or encortone or encorton or prednison acsis or predniment or decortisyl or cutason or cortan
or winpred or ultracorten or sone or sterapred or delta-dome or fernisone or paracort or predincen-m or servisone).ti,ab.
58. or/28-57
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59. Cyclizine/
60. (Cyclizine or marezine or valoid).ti,ab.
61. 59 or 60
62. Chlorpromazine/
63. (Chlorpromazine or propaphenin or aminazine or chlordelazine or contomin or largactil or fenactil or chlorazine or thorazine
or thorazine).ti,ab. (10015)
64. Domperidone/
65. (Domperidone or domperidon or apo-domperidone or domidon or domperidon-teva or gastrocure or motilium or nauzelin
or novo-domperidone or nu-domperidone or pms-domperidone or peridys or ratio-domperidone).ti,ab.
66. Droperidol/
67. (Droperidol or dehydrobenzperidol or droleptan or dehidrobenzperidol or inapsine or inapsine).ti,ab.
68. Haloperidol/
69. (Haloperidol or haldol or dozic or serenace).ti,ab.
70. Methotrimeprazine/
71. (Methotrimeprazine or levomeprazin or levopromazine or levomepromazine or tisercin or tizertsin or tizercine or levoprome
or nozinan).ti,ab.
72. Metoclopramide/
73. (Metoclopramide or metaclopramide or metaclopromide or cerucal or maxolon or primperan or raglan or rimetin).ti,ab.
74. Perphenazine/
75. (Perphenazine or chlorpiprazine or perfenazine or trilafon or fentazin).ti,ab.
76. Prochlorperazine/
77. (Prochlorperazine or compazine or stemetil or buccastem or compro).ti,ab.
78. Trifluoperazine/
79. (Trifluoperazine or trifluoroperazine or trifluperazine or stelazine or triftazin or apo-trifluoperazine or apotrifluoperazine or
eskazine or flupazine or terfluzine).ti,ab.
80. or/62-79
81. granisetron/ or odansetron/
82. granisetron.ti,ab.









92. 24 or 27 or 58 or 61 or 80 or 91
93. adolescent/ or child/ or child, preschool/ or infant/ or infant, newborn/
94. schools/ or schools, nursery/
95. (infant or infan$ or newborn or newborn$ or new-born$ or baby or baby$ or babies or neonat$ or child or child$ or schoolchild$
or schoolchild or school child or school child$ or kid or kids or toddler$ or adolescent or adoles$ or teen$ or boy$ or girl$ or minors
or minors$ or underag$ or under ag$ or juvenil$ or youth$ or kindergar$ or puberty or puber$ or pubescen$ or prepubescen$ or
prepuberty$ or pediatrics or pediatric$ or paediatric$ or peadiatric$ or schools or nursery school$ or preschool$ or pre school$ or
primary school$ or secondary school$ or elementary school$ or elementary school or high school$ or highschool$ or school age or
schoolage or school age$ or schoolage$ or infancy or schools, nursery or infant, newborn).ti,ab.
96. 93 or 94 or 95
97. Nausea/
98. nausea.ti,ab.
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123. 92 and 96 and 103 and 110 and 122
[$=zero or many characters; ti,ab=title or abstract; mp=title, abstract, subject headings, heading word, drug trade name, original title,
device manufacturer or drug manufacturer name; /= MeSH term; ab=abstract]
Search used in EMBASE/OVID
1. Benzodiazepine/ or Alprazolam/ or Anthramycin/ or Bromazepam/ or Clonazepam/ or Devazepide/ or Diazepam/ or Nordazepam/
or Flumazenil/ or Lorazepam/ or Flunitrazepam/ or Flurazepam/ or Nitrazepam/ or Oxazepam/ or Pirenzepine/ or Prazepam/ or
Temazepam/ or Chlordiazepoxide/ or Clorazepate/ or Estazolam/ or Medazepam/ or Midazolam/ or Triazolam/
2. (Alprazolam or Alprazolan or alprox or esparon or apo-alpraz or apoalpraz or cassadan or d-65mt or d65mt or kalma or novo-alprazol
or novoalprazol or nu-alpraz or nualpraz or ralozam or u-31,889 or u31,889 or xanax or tafil or trankimazin or Niravam).ti,ab.
3. (Anthramycin or antramycin).ti,ab.
4. (Bromazepam or anxyrex or apo-bromazepam or bromalich or bromaz or bromazanil or bromazep or lexotan or lexomil or lexotanil
or lexatin or ro 5-3350 or ro 53350 or durazanil or gen-bromazepam).ti,ab.
5. (Clonazepam or antelepsin or rivotril or ro 5-4023 or ro 54023 or klonopin).ti,ab.
6. (Devazepide or mk-329 or mk329).ti,ab.
7. (Diazepam or apaurin or diazemuls or faustan or relanium or seduxen or sibazon or stesolid or valium or rimapam or tensium or
dialar or valclair or diastat or dizac or q-pam or valrelease).ti,ab.
8. (Nordazepam or demethyldiazepamor desmethyldiazepam or deoxydemoxepam or nordiazepam or norprazepam or dealkylprazepam
or calmday or nordaz or tranxilium n or vegesan).ti,ab.
9. (Flumazenil or flumazepil or romazicon or anexate or lanexat or ro 15-1788 or ro 151788 or Anexate).ti,ab.
10. (Lorazepam or apo-lorazepam or apolorazepam or ativan or orfidal or temesta or donix or duralozam or durazolam or idalprem or
laubeel or lorazep von ct or novo-lorazem or novolorazem or nu-loraz or nuloraz or sedicepan or sinestron or somagerol or tolid or wy-
4036 or wy4036 or loraz).ti,ab.
11. (Flunitrazepam or fluridrazepam or flunitrazepam-teva or flunizep von ct or ro-5-4200 or ro54200 or flunimerck or flunitrazepam-
neuraxpharm or flunitrazepam-ratiopharm or fluninoc or rohypnol or narcozep or rohipnol or flunibeta).ti,ab.
12. (Flurazepam or dalmane or Dormodor or dalmadorm or staurodorm or apo-flurazepam).ti,ab.
13. (Nitrazepam or Nitrodiazepam or alodorm or dormalon or dormo-puren or eatan or imadorm or imeson or mogadon or nitrazadon
or nitrazep or novanox or radedorm or remnos or rhoxal-nitrazepam or serenade or somnite).ti,ab.
14. (Oxazepam or adumbran or serax or tazepam).ti,ab.
15. (Pirenzepine or pirenzepin or pyrenzepine or ulcoprotect or ulgescum or gastrotsepin or piren-basan or pirenzepin-ratiopharm or
gastrozepin).ti,ab.
16. (Prazepam or centrax or demetrin or lysanxia or reapam).ti,ab.
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17. (Temazepam or 3-hydroxydiazepam or hydroxydiazepam or methyloxazepam or oxydiazepam or pronervon t or remestan or restoril
or ro-5-5345 or ro55345 or sah 47-603 or sah 47603 or apo-temazepam or euhypnos or planum or levanxol or pms-temazepam or nu-
temazepam or novo-temazepam or nortem or normitab or normison or nocturne or temtabs or gen-temazepam or dasuen or signopam
or temaze or temazep von ct or tenox or wy-3917 or wy3917 or temaz).ti,ab.
18. (Chlordiazepoxide or methaminodiazepoxide or chlozepid or elenium or librium or a-poxide or chlordiazachel or librelease or
libritabs or lygen).ti,ab.
19. (Chlorazepate or tranxene or tranxilium).ti,ab.
20. (Estazolam or nuctalon or prosom or tasedan).ti,ab.
21. (Medazepam or nobrium or ro 5-4556 or ro 54556 or rudotel or rusedal).ti,ab.
22. (Midazolam or dormicum or ro 21-3981 or ro 213981 or versed or hypnovel).ti,ab.
23. (Triazolam or apo-triazo or gen-triazolam or halcyon or halcion or trilam).ti,ab.
24. or/1-23
25. Cannabinoid/ or Tetrahydrocannabinol/ or Cannabinol/ or Cannabidiol/
26. (cannabinoid$ or canabinoid$ or Tetrahydrocannabinol or thc or marinol or nabilone or cesamet).ti,ab.
27. 25 or 26
28. Beclometasone/
29. (Beclomethasone or beclometasone or qvar or aerobec forte or beclazone or ecobec or filair or aerobec or nasobec aqueous or prolair
or respocort or ventolair or vancenase or vanceril or aldecin or viarin or apo-beclomethasone or ascocortonyl or beclamet or beclocort or
beclomet or beclorhinol or becloturmant or sanasthmax or beclovent or beconase or propaderm or sanasthmyl or becodisks or becotide
or becloforte or bronchocort or junik or asmabec clickhaler or beclazone or clenil modulate).ti,ab.
30. Betamethasone/
31. (Betamethasone or betadexamethasone or flubenisolone or celeston or celestona or celestone or cellestoderm or Betnelan or
betnesol).ti,ab.
32. Betamethasone Valerate/
33. (betamethasone 17-valerate or flubenisolonvalerate or betnovate or Beta-val or betaderm or betatrex or dermabet or luxiq or valisone
or valnac or betacap or betamethasone valerate or bettamousse or diprosone).ti,ab.
34. Budesonide/
35. (Budesonide or horacort or pulmicort or rhinocort or novolizer or entocort).ti,ab.
36. Dexamethasone/
37. (Dexamethasone or hexadecadrol ormethylfluorprednisolone or dexpak ormaxidex or decaject or decameth or decaspray or dexasone
or hexadrol or millicorten or oradexon or aeroseb-dex or decaderm dexamethasone or decadron or decadron or mymethasone).ti,ab.
38. Dexamethasone Isonicotinate/
39. (dexamethasone isonicotinate or auxison).ti,ab.
40. Flumetasone/
41. (Flumethasone or fluorodexamethasone or locorten).ti,ab.
42. Fluorometholone/
43. (Fluorometholone or cortisdin or flucon or fluoro-ophtal or fml or pms-fluorometholone or fluoropos or oxylone).ti,ab.
44. fluprednisolone/
45. (fluprednisolone or alphadrol).ti,ab.
46. Fludroxycortide/
47. (Flurandrenolone or flurandrenolide or cordran or haelan or fludroxycortide).ti,ab.
48. melengestrol acetate/
49. (melengestrol acetate or melengestrol).ti,ab.
50. Methylprednisolone/
51. (Methylprednisolone or metipred or medrol or urbason or medrone or solu-medrone or depo-medrone).ti,ab.
52. Methylprednisolone Sodium Succinate/
53. (a-methapred or solu-medrol or solumedrol or urbason-soluble or urbasonsoluble).ti,ab.
54. Prednisolone/
55. (Prednisolone or di-adreson-f or diadresonf or predate or predonine or cortalone or delta-cortef or fernisolone-p or meti-derm or
prelone or sterane).ti,ab.
56. Prednisone/
57. (Prednisone or dehydrocortisone or delta-cortisone or prednison galen or prednison hexal or pronisone or rectodelt or apo-
prednisone or cortancyl or panafcort or dacortin or deltasone or prednidib or predni tablinen or panasol or orasone or meticorten or
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liquid pred or kortancyl or enkortolon or encortone or encorton or prednison acsis or predniment or decortisyl or cutason or cortan
or winpred or ultracorten or sone or sterapred or delta-dome or fernisone or paracort or predincen-m or servisone).ti,ab.
58. or/28-57
59. Cyclizine/
60. (Cyclizine or marezine or valoid).ti,ab.
61. 59 or 60
62. Chlorpromazine/
63. (Chlorpromazine or propaphenin or aminazine or chlordelazine or contomin or largactil or fenactil or chlorazine or thorazine or
thorazine).ti,ab.
64. Domperidone/
65. (Domperidone or domperidon or apo-domperidone or domidon or domperidon-teva or gastrocure or motilium or nauzelin or
novo-domperidone or nu-domperidone or pms-domperidone or peridys or ratio-domperidone).ti,ab.
66. Droperidol/
67. (Droperidol or dehydrobenzperidol or droleptan or dehidrobenzperidol or inapsine or inapsine).ti,ab.
68. Haloperidol/
69. (Haloperidol or haldol or dozic or serenace).ti,ab.
70. Levomepromazine/
71. (Methotrimeprazine or levomeprazin or levopromazine or levomepromazine or tisercin or tizertsin or tizercine or levoprome or
nozinan).ti,ab.
72. Metoclopramide/
73. (Metoclopramide or metaclopramide or metaclopromide or cerucal or maxolon or primperan or raglan or rimetin).ti,ab.
74. Perphenazine/
75. (Perphenazine or chlorpiprazine or perfenazine or trilafon or fentazin).ti,ab.
76. Prochlorperazine/
77. (Prochlorperazine or compazine or stemetil or buccastem or compro).ti,ab.
78. Trifluoperazine/
79. (Trifluoperazine or trifluoroperazine or trifluperazine or stelazine or triftazin or apo-trifluoperazine or apotrifluoperazine or eskazine
or flupazine or terfluzine).ti,ab.
80. or/62-79
81. granisetron/ or ondansetron/
82. granisetron.ti,ab.




87. (kytril or Eutrom or Kevatril or Taraz).ti,ab.




92. 24 or 27 or 58 or 61 or 80 or 91
93. NAUSEA/ or “ANTICIPATORY NAUSEA AND VOMITING”/ or “NAUSEA AND VOMITING”/
94. nausea.ti,ab.
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118. infant/ or infancy/ or newborn/ or baby/ or child/ or preschool child/ or school child/
119. adolescent/ or juvenile/ or boy/ or girl/ or puberty/ or prepuberty/ or pediatrics/
120. primary school/ or high school/ or kindergarten/ or nursery school/ or school/
121. (infant$ or newborn$ or new born$ or baby or baby$ or babies or neonate$).mp.
122. (child$ or school child$ or schoolchild$ or school age$ or schoolage$ or pre school$ or preschool$).mp.
123. (kid or kids or toddler$ or adoles$ or teen$ or boy$ or girl$).mp.
124. (minors$ or under ag$ or underage$ or juvenil$ or youth$).mp.
125. (puber$ or pubescen$ or prepubescen$ or prepubert$).mp.
126. (pediatric$ or paediatric$ or peadiatric$).mp.
127. (school or schools or high school$ or highschool$ or primary school$ or nursery school$ or elementary school or secondary
school$ or kindergar$).mp.
128. or/118-127
129. 92 and 99 and 105 and 117 and 128
[$=zero or many characters; ti,ab=title or abstract; mp=title, abstract, subject headings, heading word, drug trade name, original title,
device manufacturer or drug manufacturer name; /= Emtree term; ab=abstract]
Search used in LILACS/ http://bases.bireme.br/cgi-bin/wxislind.exe/iah/online/
(Benzodiazepine$ or Alprazolam or Alprazolan or alprox or esparon or apo-alpraz or apoalpraz or cassadan or kalma or novo-alprazol
or novoalprazol or nu-alpraz or nualpraz or ralozam or xanax or tafil or trankimazin or Niravam or Anthramycin or antramycin or
Bromazepam or anxyrex or apo-bromazepam or bromalich or bromaz or bromazanil or bromazep or lexotan or lexomil or lexotanil or
lexatin or durazanil or gen-bromazepam or Clonazepam or antelepsin or rivotril or klonopin or Devazepide or Diazepam or apaurin
or diazemuls or faustan or relanium or seduxen or sibazon or stesolid or valium or rimapam or tensium or dialar or valclair or diastat
or dizac or q-pam or valrelease or Nordazepam or demethyldiazepam or desmethyldiazepam or deoxydemoxepam or nordiazepam
or norprazepam or dealkylprazepam or calmday or nordaz or tranxilium n or vegesan or Flumazenil or flumazepil or romazicon or
anexate or lanexat or Anexate or Lorazepam or apo-lorazepam or apolorazepam or ativan or orfidal or temesta or donix or duralozam
or durazolam or idalprem or laubeel or lorazep von ct or novo-lorazem or novolorazem or nu-loraz or nuloraz or sedicepan or sinestron
or somagerol or tolid or loraz or Flunitrazepam or fluridrazepam or flunitrazepam-teva or flunizep or flunimerck or flunitrazepam-
neuraxpharm or flunitrazepam-ratiopharm or fluninoc or rohypnol or narcozep or rohipnol or flunibeta or Flurazepam or dalmane
or Dormodor or dalmadorm or staurodorm or apo-flurazepam or Nitrazepam or Nitrodiazepam or alodorm or dormalon or dormo-
puren or eatan or imadorm or imeson or mogadon or nitrazadon or nitrazep or novanox or radedorm or remnos or rhoxal-nitrazepam
or serenade or somnite or Oxazepam or adumbran or serax or tazepam or Pirenzepine or pirenzepin or pyrenzepine or ulcoprotect
or ulgescum or gastrotsepin or piren-basan or pirenzepin-ratiopharm or gastrozepin or Prazepam or centrax or demetrin or lysanxia
or reapam or Temazepam or hydroxydiazepam or methyloxazepam or oxydiazepam or pronervon t or remestan or restoril or apo-
temazepam or euhypnos or planum or levanxol or pms-temazepam or nu-temazepam or novo-temazepam or nortem or normitab
or normison or nocturne or temtabs or gen-temazepam or dasuen or signopam or temaze or temazep von ct or tenox or temaz or
Chlordiazepoxide or methaminodiazepoxide or chlozepid or elenium or librium or a-poxide or chlordiazachel or librelease or libritabs or
lygen or Chlorazepate or tranxene or tranxilium or Estazolam or nuctalon or prosom or tasedan orMedazepam or nobrium or rudotel or
rusedal or Midazolam or dormicum or versed or hypnovel or Triazolam or apo-triazo or gen-triazolam or halcyon or halcion or trilam or
cannabinoid$ or canabinoid$ or Tetrahydrocannabinol or thc or marinol or nabilone or cesamet or Beclomethasone or beclometasone
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or qvar or aerobec forte or beclazone or ecobec or filair or aerobec or nasobec aqueous or prolair or respocort or ventolair or vancenase or
vanceril or aldecin or viarin or apo-beclomethasone or ascocortonyl or beclamet or beclocort or beclomet or beclorhinol or becloturmant
or sanasthmax or beclovent or beconase or propaderm or sanasthmyl or becodisks or becotide or becloforte or bronchocort or junik or
asmabec clickhaler or beclazone or clenil modulate or Betamethasone or betadexamethasone or flubenisolone or celeston or celestona or
celestone or cellestoderm or Betnelan or betnesol or flubenisolonvalerate or betnovate or Beta-val or betaderm or betatrex or dermabet
or luxiq or valisone or valnac or betacap or betamethasone valerate or bettamousse or diprosone or Budesonide or horacort or pulmicort
or rhinocort or novolizer or entocort or Dexamethasone or hexadecadrol or methylfluorprednisolone or dexpak or maxidex or decaject
or decameth or decaspray or dexasone or hexadrol or millicorten or oradexon or aeroseb-dex or decaderm dexamethasone or decadron
or decadron or mymethasone or auxison or Flumethasone or fluorodexamethasone or locorten or Fluorometholone or cortisdin or
flucon or fluoro-ophtal or fml or pms-fluorometholone or fluoropos or oxylone or fluprednisolone or alphadrol or Flurandrenolone or
flurandrenolide or cordran or haelan or fludroxycortide or melengestrol acetate or melengestrol or Methylprednisolone or metipred or
medrol or urbason or medrone or solu-medrone or depo-medrone or a-methapred or solu-medrol or solumedrol or urbason-soluble
or urbasonsoluble or Prednisolone or di-adreson-f or diadresonf or predate or predonine or cortalone or delta-cortef or fernisolone-
p or meti-derm or prelone or sterane or Prednisone or dehydrocortisone or delta-cortisone or prednison galen or prednison hexal or
pronisone or rectodelt or apo-prednisone or cortancyl or panafcort or dacortin or deltasone or prednidib or predni tablinen or panasol
or orasone or meticorten or liquid pred or kortancyl or enkortolon or encortone or encorton or prednison acsis or predniment or
decortisyl or cutason or cortan or winpred or ultracorten or sone or sterapred or delta-dome or fernisone or paracort or predincen-
m or servisone or Cyclizine or marezine or valoid or Chlorpromazine or propaphenin or aminazine or chlordelazine or contomin
or largactil or fenactil or chlorazine or thorazine or thorazine or Domperidone or domperidon or apo-domperidone or domidon or
domperidon-teva or gastrocure or motilium or nauzelin or novo-domperidone or nu-domperidone or pms-domperidone or peridys or
ratio-domperidone or Droperidol or dehydrobenzperidol or droleptan or dehidrobenzperidol or inapsine or inapsine or Haloperidol
or haldol or dozic or serenace or Methotrimeprazine or levomeprazin or levopromazine or levomepromazine or tisercin or tizertsin
or tizercine or levoprome or nozinan or Metoclopramide or metaclopramide or metaclopromide or cerucal or maxolon or primperan
or raglan or rimetin or Perphenazine or chlorpiprazine or perfenazine or trilafon or fentazin or Prochlorperazine or compazine or
stemetil or buccastem or compro or Trifluoperazine or trifluoroperazine or trifluperazine or stelazine or triftazin or apo-trifluoperazine
or apotrifluoperazine or eskazine or flupazine or terfluzine or granisetron or odansetron or ondansetron or tropisetron or dolasetron or
anzemet or kytril or Eutrom or Kevatril or Taraz or zofran or Zofrene or Zophran or Zophren or Avessa or Ceramos)
and
(cancer$ OR neoplas$ OR oncolog$ OR malignan$ OR tumor$ OR tumour$ OR carcinoma$ OR adenocarcinoma$ OR carcoma$
OR leukaemia OR leukemia OR chemotherap$)
and
(nausea OR vomit$ OR emesis OR sickness)
[$=zero or many characters]
Search used in PsycINFO/OVID
1. benzodiazepines/ or alprazolam/ or chlordiazepoxide/ or clonazepam/ or diazepam/ or flunitrazepam/ or flurazepam/ or
lorazepam/ or midazolam/ or nitrazepam/ or oxazepam/ or triazolam/
2. (Alprazolam or Alprazolan or alprox or esparon or apo-alpraz or apoalpraz or cassadan or d-65mt or d65mt or kalma or novo-
alprazol or novoalprazol or nu-alpraz or nualpraz or ralozam or u-31,889 or u31,889 or xanax or tafil or trankimazin or Niravam).ti,ab.
3. (Anthramycin or antramycin).ti,ab.
4. (Bromazepam or anxyrex or apo-bromazepam or bromalich or bromaz or bromazanil or bromazep or lexotan or lexomil or
lexotanil or lexatin or ro 5-3350 or ro 53350 or durazanil or gen-bromazepam).ti,ab.
5. (Clonazepam or antelepsin or rivotril or ro 5-4023 or ro 54023 or klonopin).ti,ab.
6. (Devazepide or mk-329 or mk329).ti,ab.
7. (Diazepam or apaurin or diazemuls or faustan or relanium or seduxen or sibazon or stesolid or valium or rimapam or tensium
or dialar or valclair or diastat or dizac or q-pam or valrelease).ti,ab.
8. (Nordazepam or demethyldiazepam or desmethyldiazepam or deoxydemoxepam or nordiazepam or norprazepam or dealkyl-
prazepam or calmday or nordaz or tranxilium n or vegesan).ti,ab.
9. (Flumazenil or flumazepil or romazicon or anexate or lanexat or ro 15-1788 or ro 151788 or Anexate).ti,ab.
10. (Lorazepam or apo-lorazepam or apolorazepam or ativan or orfidal or temesta or donix or duralozam or durazolam or idalprem
or laubeel or lorazep von ct or novo-lorazem or novolorazem or nu-loraz or nuloraz or sedicepan or sinestron or somagerol or tolid or
wy-4036 or wy4036 or loraz).ti,ab.
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11. (Flunitrazepamor fluridrazepamor flunitrazepam-teva or flunizep von ct or ro-5-4200or ro54200 or flunimerck or flunitrazepam-
neuraxpharm or flunitrazepam-ratiopharm or fluninoc or rohypnol or narcozep or rohipnol or flunibeta).ti,ab.
12. (Flurazepam or dalmane or Dormodor or dalmadorm or staurodorm or apo-flurazepam).ti,ab.
13. (Nitrazepam or Nitrodiazepam or alodorm or dormalon or dormo-puren or eatan or imadorm or imeson or mogadon or
nitrazadon or nitrazep or novanox or radedorm or remnos or rhoxal-nitrazepam or serenade or somnite).ti,ab.
14. (Oxazepam or adumbran or serax or tazepam).ti,ab.
15. (Pirenzepine or pirenzepin or pyrenzepine or ulcoprotect or ulgescum or gastrotsepin or piren-basan or pirenzepin-ratiopharm
or gastrozepin).ti,ab.
16. (Prazepam or centrax or demetrin or lysanxia or reapam).ti,ab.
17. (Temazepam or 3-hydroxydiazepam or hydroxydiazepam or methyloxazepam or oxydiazepam or pronervon t or remestan or
restoril or ro-5-5345 or ro55345 or sah 47-603 or sah 47603 or apo-temazepam or euhypnos or planum or levanxol or pms-temazepam
or nu-temazepam or novo-temazepam or nortem or normitab or normison or nocturne or temtabs or gen-temazepam or dasuen or
signopam or temaze or temazep von ct or tenox or wy-3917 or wy3917 or temaz).ti,ab.
18. (Chlordiazepoxide or methaminodiazepoxide or chlozepid or elenium or librium or a-poxide or chlordiazachel or librelease or
libritabs or lygen).ti,ab.
19. (Chlorazepate or tranxene or tranxilium).ti,ab.
20. (Estazolam or nuctalon or prosom or tasedan).ti,ab.
21. (Medazepam or nobrium or ro 5-4556 or ro 54556 or rudotel or rusedal).ti,ab.
22. (Midazolam or dormicum or ro 21-3981 or ro 213981 or versed or hypnovel).ti,ab.
23. (Triazolam or apo-triazo or gen-triazolam or halcyon or halcion or trilam).ti,ab.
24. or/1-23
25. cannabinoids/ or tetrahydrocannabinol/
26. (cannabinoid$ or canabinoid$ or Tetrahydrocannabinol or thc or marinol or nabilone or cesamet).ti,ab.
27. 25 or 26
28. (Beclomethasone or beclometasone or qvar or aerobec forte or beclazone or ecobec or filair or aerobec or nasobec aqueous or
prolair or respocort or ventolair or vancenase or vanceril or aldecin or viarin or apo-beclomethasone or ascocortonyl or beclamet or
beclocort or beclomet or beclorhinol or becloturmant or sanasthmax or beclovent or beconase or propaderm or sanasthmyl or becodisks
or becotide or becloforte or bronchocort or junik or asmabec clickhaler or beclazone or clenil modulate).ti,ab.
29. (Betamethasone or betadexamethasone or flubenisolone or celeston or celestona or celestone or cellestoderm or Betnelan or
betnesol).ti,ab.
30. (betamethasone 17-valerate or flubenisolonvalerate or betnovate or Beta-val or betaderm or betatrex or dermabet or luxiq or
valisone or valnac or betacap or betamethasone valerate or bettamousse or diprosone).ti,ab.
31. (Budesonide or horacort or pulmicort or rhinocort or novolizer or entocort).ti,ab.
32. Dexamethasone/
33. (Dexamethasone or hexadecadrol or methylfluorprednisolone or dexpak or maxidex or decaject or decameth or decaspray or
dexasone or hexadrol or millicorten or oradexon or aeroseb-dex or decaderm dexamethasone or decadron or decadron or mymetha-
sone).ti,ab.
34. (dexamethasone isonicotinate or auxison).ti,ab.
35. (Flumethasone or fluorodexamethasone or locorten).ti,ab.
36. (Fluorometholone or cortisdin or flucon or fluoro-ophtal or fml or pms-fluorometholone or fluoropos or oxylone).ti,ab.
37. (fluprednisolone or alphadrol).ti,ab.
38. (Flurandrenolone or flurandrenolide or cordran or haelan or fludroxycortide).ti,ab.
39. (melengestrol acetate or melengestrol).ti,ab.
40. (Methylprednisolone or metipred or medrol or urbason or medrone or solu-medrone or depo-medrone).ti,ab.
41. (a-methapred or solu-medrol or solumedrol or urbason-soluble or urbasonsoluble).ti,ab.
42. Prednisolone/
43. (Prednisolone or di-adreson-f or diadresonf or predate or predonine or cortalone or delta-cortef or fernisolone-p or meti-derm
or prelone or sterane).ti,ab.
44. (Prednisone or dehydrocortisone or delta-cortisone or prednison galen or prednison hexal or pronisone or rectodelt or apo-
prednisone or cortancyl or panafcort or dacortin or deltasone or prednidib or predni tablinen or panasol or orasone or meticorten or
liquid pred or kortancyl or enkortolon or encortone or encorton or prednison acsis or predniment or decortisyl or cutason or cortan
or winpred or ultracorten or sone or sterapred or delta-dome or fernisone or paracort or predincen-m or servisone).ti,ab.
45. or/28-44
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46. (Cyclizine or marezine or valoid).ti,ab.
47. Chlorpromazine/
48. (Chlorpromazine or propaphenin or aminazine or chlordelazine or contomin or largactil or fenactil or chlorazine or thorazine
or thorazine).ti,ab.
49. (Domperidone or domperidon or apo-domperidone or domidon or domperidon-teva or gastrocure or motilium or nauzelin
or novo-domperidone or nu-domperidone or pms-domperidone or peridys or ratio-domperidone).ti,ab.
50. (Droperidol or dehydrobenzperidol or droleptan or dehidrobenzperidol or inapsine or inapsine).ti,ab.
51. Haloperidol/
52. (Haloperidol or haldol or dozic or serenace).ti,ab.
53. (Methotrimeprazine or levomeprazin or levopromazine or levomepromazine or tisercin or tizertsin or tizercine or levoprome
or nozinan).ti,ab.
54. (Metoclopramide or metaclopramide or metaclopromide or cerucal or maxolon or primperan or raglan or rimetin).ti,ab.
55. Perphenazine/
56. (Perphenazine or chlorpiprazine or perfenazine or trilafon or fentazin).ti,ab.
57. Prochlorperazine/
58. (Prochlorperazine or compazine or stemetil or buccastem or compro).ti,ab.
59. Trifluoperazine/
60. (Trifluoperazine or trifluoroperazine or trifluperazine or stelazine or triftazin or apo-trifluoperazine or apotrifluoperazine or
eskazine or flupazine or terfluzine).ti,ab.
61. or/46-60
62. granisetron.ti,ab.




67. (kytril or Eutrom or Kevatril or Taraz).ti,ab.




72. 24 or 27 or 45 or 61 or 71
73. (infant or infan$ or newborn or newborn$ or new-born$ or baby or baby$ or babies or neonat$ or child or child$ or schoolchild$
or schoolchild or school child or school child$ or kid or kids or toddler$ or adolescent or adoles$ or teen$ or boy$ or girl$ or minors
or minors$ or underag$ or under ag$ or juvenil$ or youth$ or kindergar$ or puberty or puber$ or pubescen$ or prepubescen$ or
prepuberty$ or pediatrics or pediatric$ or paediatric$ or peadiatric$ or schools or nursery school$ or preschool$ or pre school$ or
primary school$ or secondary school$ or elementary school$ or elementary school or high school$ or highschool$ or school age or
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100. 72 and 73 and 80 and 87 and 99
[$=zero or many characters; ?=one or many characters; ti,ab=title or abstract; mp=title, abstract, subject headings, heading word, drug
trade name, original title, device manufacturer or drug manufacturer name; /= PsycInfor thesuarus term; ?= ]
Appendix 2. Search strategies for proceedings abstracts
Search used in American Society of Clinical Oncology
All meetings were searched except for the breast and prostate specific meetings (since these were expected to yield results that involved
adults).






The searches were limited to the title field and the results were deduplicated.
International Society of Paediatric Oncology (SIOP)
The site was browsed.
PDFs of the abstracts were downloaded and the text was searched for “vomiting”
Multinational Association of Supportive Care in Cancer (MASCC)
The site was browsed
ISI Proceedings: Science and Technology
#1 TS=( infan* or newborn* or (new same born*) or baby* or babies or neonat* or child* or schoolchild* or (school same child*) or
kid or kids or toddler* or adoles* or teen* or boy* or girl* or minors* or underag* or juvenil* or youth* or kindergar* or puber* or
pubescen* or prepubescen* or prepuber* or pediatric* or paediatric* or peadiatric* or schools or preschool* or highschool* or (school
same age*) or schoolage*)
#2 TS=(nausea or vomit*or emesis or sickness)
#3 TS=(cancer* or neoplas* or oncolog* or malignan* or tumor* or tumour* or carcinoma* or adenocarcinoma* or sarcoma* or
leukaemia or leukemia or chemotherap*)
#1 and #2 and #3
[*=zero or many characters]
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Appendix 3. Search strategies for trial registers
International Cancer Research Portfolio
The following selections were made:
Project Type=Clinical Trial
Type of Research=6.1 Cancer Control, Survivorship and Outcomes Research - Patient Care and Survivorship Issues
There was a limit on the number of terms that could be entered in the search box, so the searching was done in the following batches:
(N.B. the default is to “OR” all terms)
Search one:
Benzodiazepine$ Alprazolam Alprazolan alprox esparon apo-alpraz apoalpraz cassadan kalma novo-alprazol novoalprazol nu-alpraz
nualpraz ralozam xanax tafil trankimazin Niravam Anthramycin antramycin Bromazepam anxyrex apo-bromazepam bromalich bromaz
bromazanil bromazep lexotan lexomil lexotanil lexatin durazanil gen-bromazepam
Search two:
Clonazepam antelepsin rivotril klonopin Devazepide Diazepam apaurin diazemuls faustan relanium seduxen sibazon stesolid valium
rimapam tensium dialar valclair diastat dizac q-pam valrelease Nordazepam demethyldiazepam desmethyldiazepam deoxydemoxepam
nordiazepam norprazepam dealkylprazepam
Search three:
calmday nordaz tranxilium Flumazenil flumazepil romazicon anexate lanexat Anexate Lorazepam apo-lorazepam apolorazepam ativan
orfidal temesta donix duralozam durazolam idalprem laubeel lorazep von ct novo-lorazem novolorazem nu-loraz nuloraz sedicepan
sinestron
Search four:
somagerol tolid loraz Flunitrazepam fluridrazepam flunitrazepam-teva flunizep flunimerck flunitrazepam-neuraxpharm flunitrazepam-
ratiopharm fluninoc rohypnol narcozep rohipnol flunibeta Flurazepam dalmane Dormodor dalmadorm staurodorm apo-flurazepam
Nitrazepam Nitrodiazepam
Search five:
alodorm dormalon dormo-puren eatan imadorm imeson mogadon nitrazadon nitrazep novanox radedorm remnos rhoxal-nitrazepam
serenade somnite Oxazepam adumbran serax tazepam Pirenzepine pirenzepin pyrenzepine ulcoprotect ulgescum gastrotsepin piren-
basan
Search six:
pirenzepin-ratiopharm gastrozepin Prazepam centrax demetrin lysanxia reapam Temazepam hydroxydiazepam methyloxazepam oxy-
diazepam pronervon remestan restoril apo-temazepam euhypnos planum levanxol pms-temazepam nu-temazepam novo-temazepam
nortem normitab
Search seven:
normison nocturne temtabs gen-temazepam dasuen signopam temaze temazep tenox temaz Chlordiazepoxide methaminodiazepoxide
chlozepid elenium librium a-poxide chlordiazachel librelease libritabs lygen Chlorazepate tranxene tranxilium Estazolam nuctalon
prosom tasedan
Search eight:
Medazepam nobrium rudotel rusedalMidazolam dormicum versed hypnovel Triazolam apo-triazo gen-triazolam halcyon halcion trilam
cannabinoid$ canabinoid$ Tetrahydrocannabinol thcmarinol nabilone cesamet Beclomethasone beclometasone qvar aerobec beclazone
ecobec
Search nine:
filair aerobec nasobec prolair respocort ventolair vancenase vanceril aldecin viarin apo-beclomethasone ascocortonyl beclamet beclocort
beclomet beclorhinol becloturmant sanasthmax beclovent beconase propaderm sanasthmyl becodisks becotide becloforte
Search 10:
bronchocort junik asmabec beclazone clenil Betamethasone betadexamethasone flubenisolone celeston celestona celestone cellestoderm
Betnelan betnesol flubenisolonvalerate betnovate Beta-val betaderm betatrex dermabet luxiq valisone valnac betacap betamethasone
Search 11:
valerate bettamousse diprosone Budesonide horacort pulmicort rhinocort novolizer entocort Dexamethasone hexadecadrol methylflu-
orprednisolone dexpak maxidex decaject decameth decaspray dexasone hexadrol millicorten oradexon aeroseb-dex decaderm dexam-
ethasone decadron
Search 12:
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decadron mymethasone auxison Flumethasone fluorodexamethasone locorten Fluorometholone cortisdin flucon fluoro-ophtal fml
pms-fluorometholone fluoropos oxylone fluprednisolone alphadrol Flurandrenolone flurandrenolide cordran haelan fludroxycortide
melengestrol acetate melengestrol
Search 13:
Methylprednisolone metipred medrol urbason medrone solu-medrone depo-medrone a-methapred solu-medrol solumedrol urbason-
soluble urbasonsoluble Prednisolone di-adreson-f diadresonf predate predonine cortalone delta-cortef fernisolone-p meti-derm prelone
sterane Prednisone
Search 14:
dehydrocortisone delta-cortisone prednisonpronisone rectodelt apo-prednisone cortancyl panafcort dacortin deltasone prednidib predni
panasol orasone meticorten kortancyl enkortolon encortone encorton predniment decortisyl cutason
Search 15:
levomepromazine tisercin tizertsin tizercine levoprome nozinan Metoclopramide metaclopramide metaclopromide cerucal maxolon
primperan raglan rimetin Perphenazine chlorpiprazine perfenazine trilafon fentazin Prochlorperazine compazine stemetil buccastem
compro Trifluoperazine
Search 16:
trifluoroperazine trifluperazine stelazine triftazin apo-trifluoperazine apotrifluoperazine eskazine flupazine terfluzine
Search 17:
5-HT3 antagonists 5-HT3 antagonist 5-HT3 blockers 5-HT3 blocker
Search 18:
granisetron ondansetron ondansetron tropisetron dolasetron anzemet kytril Eutrom Kevatril Taraz zofran Zofrene Zophran Zophren
Avessa Ceramos
[$=zero or more characters]
National Cancer Institute Clinical Trials PDQ
The interface uses menu selections there is no free text searching. The following selections were made:
Type of cancer:all
Type of trial:supportive care
Status of trial:active/closed (this was an either/or situation the same search was run twice once for active, once for closed)
Type of treatment:chemotherapy
Drug:alprazolam, lorazepam, midazolam,midazolam hydrochloride, cannabinol, tetrahydrocannabinol, beclomethasone dipropionate, budes-
onide, dexamethasone, Sk-Dexamethasone, 6Alpha-Methylprednisolone, 9alpha-Fluoro-16alpha- methylprednisolone, 9Alpha-fluoro-16al-
pha-methylprednisolone, methylprednisolone, Methylprednisolone Acetate, Methylprednisolone Succinate, prednisolone, prednisone, Sk-Pred-





National Cancer Research Institute (NCRI)
The site was browsed.
Current Controlled Trials (mRCT Register)
(cancer% OR neoplas% OR oncolog% OR malignan% OR tumor% OR tumour% OR carcinoma% OR adenocarcinoma% OR
carcoma% OR leukaemia OR leukemia OR chemotherap%) and (nausea OR vomit% OR emesis OR sickness)
[%=zero or many characters]
Search used in Clinical Trials.gov
(Cancer OR carcinoma OR leukaemia OR leukemia) and (nausea OR vomit)
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Centerwatch
The interface uses a combination of menu selections and free text searching. The following selection was made:
Disease or condition: Cancer/Chemotherapy
All other boxes were left blank.
Keywords used were: vomit or nausea or emesis or sickness
WH A T ’ S N E W
Last assessed as up-to-date: 16 December 2014.
Date Event Description
15 September 2015 New citation required but conclusions have not
changed
Summary of most important changes in the update:
The search for eligible studies was updated to De-
cember 2014; we identified six new studies. They in-
cluded comparisons of different 5-HT3 antagonists,
and the addition of further agents to 5-HT3 antagonist
’backbone’ antiemetic strategies (including traditional
Chinese medicine, anxiolytics, and other antiemetics).
These new studies did not meaningfully alter the con-
clusions of the 2010 review
2 January 2015 New search has been performed The search for eligible studies was updated to Decem-
ber 2014
H I S T O R Y
Protocol first published: Issue 2, 2009
Review first published: Issue 9, 2010
Date Event Description
18 January 2011 Amended Contact details updated.
98Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C O N T R I B U T I O N S O F A U T H O R S
RSP took part in protocol development, search formulation, initial screening, data extraction and data synthesis, and drafted the report.
AJF undertook screening and data extraction of the 2014 update, and drafted the updated report.
FG took part in protocol development and drafted the report.
EH undertook data extraction and data synthesis.
SG undertook screening and data extraction, and drafted the report.
JVC took part in protocol development and data extraction.
BP took part in protocol development, undertook data extraction and synthesis, and drafted the report.
All review authors have contributed to the final report.
D E C L A R A T I O N S O F I N T E R E S T
RSP: no financial conflicts of interest
AJF: no financial conflicts of interest
FG: no financial conflicts of interest
EH: no financial conflicts of interest
SG: no financial conflicts of interest
JVC: no financial conflicts of interest
BP: no financial conflicts of interest
S O U R C E S O F S U P P O R T
Internal sources
• Candlelighters: The Yorkshire Children’s Cancer Charity, UK.
Financial support for RSP and the conduct of the original review
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
1. The objectives were clarified; the overarching aim was supplemented with specific objectives.
2. We explicitly excluded non-pharmacological therapies in the text of this review, instead of implying it in the text of the protocol.
3. We used marginally different search filters. After discussion within the team, it was felt that the Centre for Reviews and
Dissemination (CRD) search filters, which are used to undertake many Health Technology Appraisal reports from the CRD, were the
most appropriate filters to apply. Sampling 200 random citations ’missed’ with the CRD filter did not demonstrate any additional
relevant studies.
4. During data extraction we also collected data on “potential for selective reporting of outcomes” and “other potential sources of
bias” (particularly in respect to cross-over studies). This was advised following the initial protocol.
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5. The explicit analysis of outcomes to assess for the effect of potential sources of bias, including publication bias, was undertaken
but not explicitly stated in the original protocol.
6. We stated that we would not assess any outcome where more than 50% of participants did not have that outcome. In no trial
was there a drop-out rate that high, and so we did not drop any assessments for this reason.
7. We did not specify the type of analysis of paired/cross-over data in the protocol.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Antiemetics [adverse effects; ∗therapeutic use]; Antineoplastic Agents [∗adverse effects]; Dexamethasone [therapeutic use]; Drug Ther-
apy, Combination [adverse effects; methods]; Nausea [chemically induced; ∗drug therapy; ∗prevention & control]; Neoplasms [drug
therapy]; Randomized Controlled Trials as Topic; Serotonin Antagonists [adverse effects; therapeutic use]; Vomiting [chemically in-
duced; ∗drug therapy; ∗prevention & control]
MeSH check words
Adolescent; Child; Humans
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